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Summary 
 
αLβ2 is expressed on all leukocytes and plays a major role in immune responses by regulating cell 
adhesion, leukocyte trafficking, T cell costimulation and immunological synapse (IS) formation. 
This integrin is centrally involved in immune-mediated diseases of high medical need, including 
chronic plaque psoriasis, multiple sclerosis, rheumatoid arthritis, small vessel vasculitis, dry eye 
disease and transplantation indications, among other diseases. In several of these diseases, αLβ2 has 
been validated by biologic therapies as a target of high therapeutic potential. 
 
In the first part (paper) of this thesis we describe the identification and preclinical characterization 
of a novel class of αLβ2 inhibitors. These novel compounds with an allosteric mechanism of action, 
(also termed α I allosteric inhibitors), were designed to overcome major unwanted effects of current 
αLβ2 targeting drugs. Drug candidates derived from this project are foreseen to be assessed 
clinically in αLβ2-mediated disease of high unmet medical need.  
Computer-assisted drug design (CADD) has been used to identify hits that modulate αLβ2 function 
via binding to the I allosteric site. The CADD approach pursued addressed the task of finding novel 
hits and leads from two conceptually complementary angles: (1) ligand-based similarity searching 
from known allosteric αLβ2 modulators but structurally different bioactive compounds, and (2) 
structure-based similarity searching with the aim to find novel allosteric αLβ2 modulators. A 
collection of several million commercially available compounds with drug-like properties has been 
compiled. These virtual screens yielded in ranked lists of compounds.  
To determine the activity of these hits, an adhesion assay has been established (V well adhesion 
assay) to measure the binding of leukocytes (expressing αLβ2) to recombinant intercellular 
adhesion molecule-1 (ICAM-1), the ligand of αLβ2.  
The α I allosteric mode of action of the compounds has been confirmed by quantifying the binding 
of the anti- αLβ2 mAb R7.1. 
The novel and potent αLβ2 silencing compounds identified were chemically derivatized employing 
also CADD technologies. Based on first SAR data and CADD feedback, the scaffold of the lead 
compound has been modified.  
These newly synthesized αLβ2 inhibitors discovered do not induce “agonistic” effects such as αLβ2 
internalization (as observed in same experiments with biologics), induction of αLβ2 activation 
epitopes (as observed in same experiments with ligand mimetic α/β I allosteric αLβ2 inhibitors), 
and induction of ZAP70 phosphorylation. Moreover, they do not interfere with the 
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internalization/recycling of engaged T cell receptor/CD3 complexes and they do not show in vitro 
cytotoxicity. 
The lead drug candidate identified, characterized and optimized has been transitioned to preclinical 
pharmacokinetic (PK) characterization and formulation development in vivo. 
 
In the second part (paper) of this thesis we systematically compared different modes of αLβ2 
inhibition for their αLβ2 inhibitory as well as their potential unwanted downstream events, such as 
paradoxic agonism. 
Three major classes of αLβ2 inhibitors with distinct modes of action have been described to date: 
monoclonal antibodies (mAbs), small molecule α/β I allosteric and small molecule α I allosteric 
inhibitors. All inhibitors assessed were found to potently block αLβ2-mediated leukocyte adhesion 
in the low nanomolar to picomolar range. None of the inhibitors induced ZAP70 phosphorylation, 
indicating absence of agonistic outside-in signalling. 
Paradoxically, however, the α/β I allosteric inhibitor XVA143 induced conformational changes 
within αLβ2 characteristic for an intermediate affinity state, an effect that was not observed with the 
α I allosteric inhibitor LFA878 or the anti- αLβ2 mAb efalizumab. 
On the other hand, efalizumab triggered the unscheduled internalization of αLβ2 while LFA878 and 
XVA143 did not affect or only mildly reduced αLβ2 surface expression, respectively. 
Moreover, anti-αLβ2 mAb efalizumab, in contrast to the small molecule inhibitors, disturbed the 
fine-tuned internalization/recycling of engaged T cell receptor/CD3 complexes, concomitantly 
decreasing intracellular ZAP70 expression levels. 
In conclusion, different modes of αLβ2 inhibition are associated with fundamentally different 
biologic effect profiles. The differential established here provides important translational guidance 
for novel αLβ2 inhibitors. 
 
In the third part (paper) we described a flow cytometry-based technology that simultaneously 
quantitates αLβ2 conformational change upon inhibitor binding, αLβ2 expression and T cell 
activation at the single-cell level in human blood. Two classes of allosteric low molecular weight 
inhibitors, designated α I and α/β I allosteric αLβ2 inhibitors, were investigated.  
The multi-parameter whole blood αLβ2 assay described may enable therapeutic monitoring of αLβ2 
inhibitors in patients’ blood. The assay dissects differential effect profiles of different classes of 
αLβ2 inhibitors. 
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The flow cytometry-based technology described allows, for the first time, to simultaneously assess 
and correlate, at the single-cell level, inhibitor-specific αLβ2 conformational change, αLβ2 
expression and T cell activation in human whole blood. 
The format, robustness and sensitivity of the assay indicate that it may be suitable for bedside 
monitoring of newly developed αLβ2 inhibitors. 
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Aims 
 
The first aim of this thesis was the identification and characterisation of novel allosteric αLβ2 
inhibitors, which stabilize the integrin in its inactive conformation. The second aim was to 
differentiate these new allosteric inhibitors from other αLβ2 inhibitors with different modes of 
actions. The third aim was to provide novel methods to enable the pharmacodynamic 
characterization of low molecular weight αLβ2 inhibitors. 
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1. Introduction 
 
1.1. Integrins 
Integrins are a superfamily of 24 members known to date. They are heterodimeric cell-surface 
receptors composed of one alpha subunit and one beta subunit each, non-covalently associated; in 
vertebrates 18 alpha subunits and 8 beta subunits exist (Fig. 1). Functionally, integrins are cellular 
adhesion molecules mediating a wide range of cell-cell, cell-extracellular matrix and cell-pathogen 
interactions (Tan 2012). 
The first integrin was identified almost 31 years ago, by Tamkun et al. (Tamkun, et al. 1986) They 
described the isolation, characterization, and sequence of cDNA clones that encode one subunit of a 
membrane glycoprotein complex, involved in the transmembrane linkage between fibronectin and 
actin. They proposed to term this type of glycoprotein complexes integrin for their ability to 
integrate extracellular and cytoskeletal environments (Campbell and Humphries 2011). 
 
 
Fig. 1. Classification of integrin family of heterodimers. The nine α 
domains with “inserted” I domains (1, 2, 10, 11, D, L, M, X, E) are 
indicated in red (Campbell and Humphries 2011). 
 
Integrins are found in a wide range of organisms: sponges, corals, nematodes, echinoderms and 
mammals (Burke 1999) and are expressed in a broad variety of cell types. Cells of the immune 
system express at least 10 members of the integrin family belonging to the β1, β2 and β7. The β2 
and β7 are expressed exclusively on leukocytes while β1 integrins are expressed on a white variety 
of cells.  
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The diversity in the subunits and in the combination of the alpha and beta chains make integrins 
able to interact with several and different ligands (Kern and Marcantonio 1998). 
Integrins can bind to extracellular matrix (ECM) glycoproteins including collagens, fibronectins, 
vitronectin, laminins, plasma proteins, complement factors, C-reactive protein and cellular receptors 
such as vascular cell adhesion molecule-1 (VCAM-1) and the intercellular cell adhesion molecule 
(ICAM) family (Fig. 2) (Hynes 2002; Plow, et al. 2000). The amino acid sequence Arg-Gly-Asp 
(RGD) present in some ligands is a common sequence recognized by several integrins (Ruoslahti 
and Pierschbacher 1986). 
 
 
Fig. 2. Classification of integrin ligands and their binding to counterpart integrins. The αA-domain (a 
von Willebrand factor A domain, vWFA) refers to the “inserted” I domain (Humphries, et al. 2006).  
 
Each integrin heterodimer presents an extracellular domain that binds the extracellular ligands, a 
transmembrane domain (TM) and an intracellular cytoplasmic domain where the alpha and beta 
tails undergo to conformational changes to interact with other proteins (Campbell and Humphries 
2011). Intriguingly, integrins integrate and transduce signals bidirectionally: “outside-in” and 
“inside-out” the cell.  
Integrins show distinctive activation state on different cell types. They are active in most adherent 
cells and inactive on platelets or leukocytes (Campbell and Humphries 2011). 
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In the normal resting, inactive state, integrin extracellular domains do not bind to ligands and exist 
in a bent conformation. Activation signals from the inside of the cell induce conformational changes 
within αLβ2 leading to an extended form which is ready to bind ligand (inside-out signalling) (Lau, 
et al. 2009). 
In outside-in signalling the binding of integrins to their ligands results in intracellular signal 
transduction like proliferation, differentiation and apoptosis (Zaidel-Bar, et al. 2007). 
Several integrins interact with their ligands via the inserted I domain on the α chain (Fig. 1). The 
ligand interaction to the I domain is dependent on divalent cations (Lee, et al. 1995). In humans, the 
I domain is present in α1, α2, α10, α11, αD, αE, αL, αM and αX (Fig. 1). The size of the I domain is 
around 200 a.a. (Johnson and Chouhan 2014). 
 
1.2. Integrins as therapeutic targets 
Integrins are interesting therapeutic target for several diseases. Thrombosis was the first disease-
related process found to be associated with integrins (Estevez, et al. 2015). 
In the mid 1960s Eduard Glanzmann, a Swiss paediatrician, described a disorder now known as 
Glanzmann thrombasthenia. Patients with this disorder suffer of serious bleeding. Their platelets 
lack integrin αIIbβ3 (GPIIb/IIIa) and/or have defective αIIbβ3 receptors. As a result, bridging of 
platelets to other platelets via fibrinogen, the ligand of aIIbb3, cannot occur, and bleeding times are 
significantly prolonged (Coller 2014). 
To date, six pharmacological inhibitors (antibodies, peptides and peptidomimetics targeting 4 
integrins) have been approved (Sawada, et al. 2012) (Holland, et al. 2016). Some other modalities 
are in clinical development (Table 1) (Chiricozzi, et al. 2016). For example, Abciximab (ReoPro®) 
is the Fab fragment of the chimeric human-murine mAb 7E3, which binds to the platelet receptor 
αIIbβ3 and to the vitronectin receptor (integrin αvβ3). Abciximab inhibits platelet aggregation that 
cause thrombus formation and is used during and after coronary artery procedures (Table 1). 
Eptifibatide (Integrilin®) is a cyclic heptapeptide derived from barbourin that contains a KGD 
sequence. It is a member of the disintegrins. Disintegrins are a class of small proteins that contains 
an RGD (Arg-Gly-Asp) or KGD (Lys-Gly-Asp) sequence motif. These motifs are able to bind to 
the αIIbβ3, blocking in this way the binding of fibrinogen to activated aIIb/b3expressed on platelets 
(Minoux, et al. 2000) (Ruoslahti and Pierschbacher 1986) 
Integrins are also essential protein for the migration and interaction of cells of the immune system. 
Both β1 and β2 integrins are important in immune functions. Mutations in β2 integrins lead to a rare 
autosomal recessive disorder, leukocyte adhesion deficiency (LAD) (Hogg and Bates 2000) (Shaw, 
et al. 2001). 
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Efalizumab (Raptiva®) is a humanized mAb directed against the αL chain of αLβ2 that was used 
for the treatment of psoriasis. In 2006 it has been withdrawn from the market because of an 
association with progressive multifocal leukoencephalopathy (PML) (Keene, et al. 2011). In July 
2016, a small molecule αLβ2 inhibitor was approved for dry eye disease (Holland, et al. 2016). 
Natalizumab (Tysabri®), a humanized mAb against the α4 subunit, is effective in the treatment of 
multiple sclerosis and Crohn’s disease (Zohren, et al. 2008). 
Integrins are also attractive anticancer targets. During the formation of metastasis, cells become 
able to migrate and invade other tissues. For this reason, compounds or antibodies that target 
integrins could be used in combination with other anticancer treatment. Etaracizumab (Abegrin®) is 
a humanized mAb against αVβ3 recently investigated for the treatment of melanoma (Landen, et al. 
2008). 
Cilengitide, a cyclic RGD-f-(NMe)V peptide specific for αVβ3 integrin, reached Phase III trials for 
the treatment of glioblastoma and other brain cancers but it was not efficacious in clinical trials that 
aimed to limit tumour angiogenesis and progression in patients with glioblastoma (Burke, et al. 
2002) (Ley, et al. 2016). 
Volociximab is a chimeric mouse/human anti α5β1 mAb. Preclinical studies have shown the ability 
of volociximab to inhibit tumour neoangiogenesis by blocking the interaction between α5β1 and 
fibronectin (Ng, et al. 2010) (Almokadem and Belani 2012). 
 
Table 1 
Overview of integrin targeting drugs which are approved or in clinical development (Sawada, et al. 2012) 
(Chiricozzi, et al. 2016) (Holland, et al. 2016). 
Target Product Company Indication Status 
αLβ2 Efalizumab 
Lifitegrast 
Genentech/Xoma 
SARcode 
Plaque psoriasis 
Dry eye disease 
Withdrawn 
Approved 
α4β1/ α4β7 
Natalizumab 
 
Firategrast 
AJM300 
Biogen Idec 
 
GSK/MTPC  
Ajinomoto 
Multiple sclerosis 
Crohn’s disease 
Multiple sclerosis 
Ulcerative colitis 
Approved 
Approved 
Phase II 
Phase II 
α4β7 
Vedolizumab 
 
MLN02 
Millennium (Takeda) 
 
 
Crohn’s disease 
Ulcerative colitis 
Ulcerative colitis 
Approved 
Approved 
Phase II 
α3 Abciximab Centocor/ E Lilly Acute coronary syndrome Approved 
α5β1 Volociximab 
ATN-161 
PDL BioPharma 
Attenuon LLC 
Ovarian cancer 
Lung, liver, spleen cancer 
Phase II 
Phase I 
α5β3 Etaracizumab Medimmune Prostate, ovarian cancer Phase II 
αIIbβ3 
Tirofiban 
Eptifibatide 
Merck/Millennium 
Millennium (Takeda) 
Acute coronary syndrome 
Acute coronary syndrome 
Approved 
Approved 
αV Intetumumab Centocor Melanoma tumourigenesis Phase II 
αVβ3/ αVβ5 Cilengitide Merck Serono 
Glioblastoma 
Lung cancer (NSC) 
Squamous cell carcinoma 
Phase III 
Phase II 
Phase II 
αVβ6 STX-100 Stromedix/Biogen Idiopathic pulmonary fibrosis Phase II 
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Interestingly, several viral pathogens interact with integrins and use them to be internalized. These 
viruses display RGD sequences on their viral capsid that can be recognized by integrins. Virus 
binding induces conformational changes and clustering of the integrins leading to cell-signalling 
events. As a consequence a rearrangement of the cytoskeleton and an internalization of the virus-
integrin complex occurs (Stewart and Nemerow 2007). 
Moreover, integrins have an important role in maturation of osteoclasts and thus for the 
development of the bones. Polymorphisms on the integrin αVβ3 are associated with increased rate 
of fractures and osteoporosis (Tofteng, et al. 2007). 
Psoriasis is a T cell-mediated autoimmune chronic inflammatory disease. The α1β1 integrin has 
been shown to be crucial for accumulation of epidermal T cells and the development of psoriasis. It 
may be possible to prevent the accumulation of epidermal T cells by blocking the interaction of 
α1β1 with collagen (Conrad, et al. 2007). The interaction of αLβ2 with ICAM-1 is another target in 
the treatment of psoriasis (Reisman, et al. 2011). 
Uveitis is a disease characterized by an inflammation of the uvea. An early step in the pathogenesis 
of this inflammatory disease is the adhesion of leukocytes to the vascular wall followed by 
leukocyte activation, firm adhesion, and transmigration into the interstitial tissue. The accumulation 
of activated leukocytes in the ocular tissues leads to damage of the uvea.  
Several preclinical studies suggest that the integrins VLA-4 and αLβ2 play major roles in uveitis. 
VLA-4 blockade by monoclonal anti-rat VLA-4 antibody, clone TA-2, suppresses endotoxin-
induced uveitis in vivo (Hafezi-Moghadam, et al. 2007). Small-molecule inhibitors of α4 integrins 
have been shown to be effective in experimental autoimmune uveitis by interfering with cell 
adhesion events (Martin, et al. 2005). Further, mAbs directed against αLβ2 or ICAM-1 can be used 
to protect against experimental uveitis (Uchio, et al. 1994) (Whitcup, et al. 1993) (Whitcup, et al. 
1995). Importantly, in a pilot study, efalizumab has been shown to be efficacious in uveitis patients 
(Faia, et al. 2011b).  
 
1.3. αLβ2 
Within the integrin superfamily, αLβ2 belongs to the beta 2 integrin subfamily, which is defined by 
a common beta 2 chain and unique alpha chain. The four members of the beta 2 integrin subfamily 
are αLβ2 (LFA-1, CD11a/CD18), αMβ2 (Mac-1, CD11b/CD18), αXβ2 (gp 150, CD11c/CD18) and 
αDβ2 (CD11d/CD18) (Tan 2012). 
In 1981 Davignon et al. used different mAbs to identify important molecules on murine cytotoxic T 
lymphocytes (CTL). They found that the binding of mAbs to an antigen involved in CTL-mediated 
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lysis leads to the inhibition of their killing functions. The clone M7/14 defined a cell surface 
antigen, termed later as leukocyte function-associated antigen 1 (LFA-1) (Davignon, et al. 1981). 
In 1982 Sanchez-Madrid et al. identified the human αLβ2 homologue of the previously described 
mouse αLβ2 antigen. The mouse and human antigens are extremely conserved. Sanchez-Madrid et 
al. also discovered five different anti-αLβ2 mAbs that inhibit the killing pathway in CTLs 
(Sanchez-Madrid, et al. 1982). 
Given its broad distribution on immunocompetent cells, αLβ2 plays a central role in immune 
mediated and inflammatory diseases. This has been established extensively in experimental disease 
in animals, mostly using knock-out mice and anti-αLβ2 antibodies. Anti-αLβ2 therapy led to 
prolonged graft survival in various models of allograft transplantation (including cardiac, islet and 
cornea transplantation). Moreover, in several transplantation models, tolerance could be induced 
with both anti-αLβ2 therapy used alone or in combination with other modalities (Nicolls and Gill 
2006) (Arefanian, et al. 2010). In other experimental disease models, for example uveitis, arthritis, 
multiple sclerosis, diabetes mellitus, asthma and lupus-like disease, animals genetically deficient for 
αLβ2 or treated with anti-αLβ2 agents were found to be protected against disease (Giblin and 
Lemieux 2006) (Ke, et al. 2007) (Glawe, et al. 2009) (Lee, et al. 2008) (Suchard, et al. 2010). 
αLβ2 has also been identified as a therapeutic target for infectious diseases, including HIV infection 
(Kapp, et al. 2013). 
Beyond, αLβ2 has been described as target receptor for drug delivery or for the delivery of marker 
molecules such as imaging agents (diagnostic usage) to lymphoma and leukemic cells (Chittasupho, 
et al. 2010) (Poria, et al. 2006). 
Further, αLβ2 plays decisive roles in the differentiation of lymphocyte populations (Verma, et al. 
2012) and may be used as a target allowing the selection or expansion of distinct lymphocyte 
populations in vitro, ex vivo and in vivo. Increases in regulatory lymphocyte populations have been 
observed in patients treated with anti-αLβ2 antibodies (Faia, et al. 2011a) (Posselt, et al. 2010). 
Taken together, it is appreciated that αLβ2 is a receptor involved in inflammatory, immune -
mediated and infectious diseases and is overexpressed in certain malignant diseases. These diseases 
are often severe, chronic disorders often requiring life-long therapy. 
The expression of αLβ2 is restricted to leukocytes including T cells, B cells, neutrophils, 
monocytes, macrophages, dendritic cells, mast cells, eosinophils, and NK cells. The level of 
expression varies with cell type and differentiation state. αLβ2 is overexpressed in certain 
lymphomas and leukemias (Poria, et al. 2006) (Chittasupho, et al. 2010). 
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αLβ2 plays a central role in the innate and adaptive immune response. Firstly, as a cellular adhesion 
molecule αLβ2 mediates the firm adhesion of leukocytes to inflamed vessel walls and their 
extravasation into inflamed tissues (Fig. 3). 
 
Fig. 3. Leukocyte extravasation into target tissues. Sequential steps of leukocyte 
extravasation. Tethering of the leukocyte occurs through interactions between selectins 
and their endothelial ligands. Firm adhesion is mediated by interaction of leukocyte 
integrins very late antigen 4 (VLA-4) and leukocyte function-associated antigen 1 
(LFA-1, αLβ2) with endothelial vascular cell-adhesion molecule 1 (VCAM-1) and 
intercellular adhesion molecule 1 (ICAM-1), respectively (Vicente-Manzanares and 
Sanchez-Madrid 2004). 
 
Secondly, αLβ2 is crucial for the activation of immune cells (Fig. 4). In this context, αLβ2 is well-
characterized as a costimulatory receptor which is essential for the formation of the immunological 
synapse (IS) and controls T cell activation and proliferation. 
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Fig. 4. The lymphocyte cytoskeleton during T cell–APC interactions and the formation of the 
immunological synapse. In the cSMAC, TCRs interact with APC bearing peptide-MHC 
complexes. Triggering of TCR leads to the activation of the kinesis LAT, FYN and ZAP70 and 
to a phosphorylation cascade. In the pSMAC, αLβ2 interacts with ICAM-1 acting as 
costimulatory receptor (Vicente-Manzanares and Sanchez-Madrid 2004).  
 
Interaction of antigen presenting cells (APC) bearing peptide-MHC complexes with T cell receptor 
(TCR) leads to the formation of the IS. Already after few seconds, T cells react with a spatial 
reorganization of proteins and with a chain reaction leading to phosphorylation and 
dephosphorylation cascades.  
The immune synapse is also known as the supramolecular activation cluster or SMAC. This 
structure is composed of concentric rings each containing segregated clusters of proteins. 
In the central ring, cSMAC, there are mainly TCR, the peripherical one, pSMAC, is composed of 
αLβ2. Studies in mouse models revealed that αLβ2/ICAM-1 interaction is also important for driving 
Th1 polarization (Mittelbrunn, et al. 2004). 
The distal ring, dSMAC, is composed of F-actin microfilaments (Philipsen, et al. 2013). The 
rearrangement of the actin shows a particular organization called actin cloud that is triggered by 
αLβ2 outside-in signals. For the actin cloud formation, TCR and ZAP70 appeared to be not 
essential (Suzuki, et al. 2007). 
After the triggering of the TCR, the kinases Lck is activated and can phosphorylate the ITAM 
sequence on the cytoplasmic domain of the CD3 subunits. ZAP70 can be now recruited to activate 
the kinase LAT. The phosphorylation cascade will lead to activate T cells through a release of 
intracellular Ca2+ flux and to the activation of the MAPK pathway (Philipsen, et al. 2013). 
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αLβ2 is also involved in the organization of cSMAC. The localization of complexes TCR/Class II 
in the cSMAC has been shown to be αLβ2 dependent (Graf, et al. 2007). 
 
1.4. αLβ2 ligands  
The ligands of αLβ2 identified to date belong to the immunoglobulin (Ig) superfamily. They are the 
intercellular adhesion molecules ICAM-1, -2, -3, -4, and -5 and the junctional adhesion molecule 
JAM-A (previously JAM-1). These ligands are expressed on various cell types including 
endothelial cells on the vessel wall, epithelial and tissue resident cells (i.e. keratinocytes, dendritic 
cells) and leukocytes (Tan 2012). 
The five members of the ICAM family express different numbers of Ig-like C2 type domain (Fig. 5) 
and they have different functions and cell distributions (Xiao, et al. 2013). 
 
 
Fig. 5. Schematic primary structures of ICAMs. ICAMs belong to the 
immunoglobulin superfamily. Each molecule is composed of several 
Immunoglobulin-like domains in the extracellular region, a short 
transmembrane region, and a cytoplasmic tail (Xiao, et al. 2013). 
 
In 1986 Rothlein et al. (Rothlein, et al. 1986) identified and characterized ICAM-1 as one of the 
molecules involved in homotypic aggregation of leukocytes. In their experiments, JY B 
lymphoblastoid cells were stimulated with phorbol 12-myristate 13-acetate (PMA). PMA 
stimulation leads to cell aggregation (Rothlein and Springer 1986). Using the mAb RR1/1 a mAb 
that targets the antigen RR1/1, later defined as ICAM-1, they showed that this antibody prevents 
cell homotypic aggregation. ICAM-1 is expressed on fibroblasts, endothelial cells and its expression 
is increased in response to IL-1 and other cytokines (Rothlein, et al. 1986). 
LPS, Thrombin, IL-1, PMA, VEGF, and shear stress also induce expression of ICAM-1 (Rahman 
and Fazal 2009). 
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In 1987 Corbi et al. showed that ICAM-1 binding to αLβ2 is dependent on the by divalent cations 
Mg2+ and Ca2+ at physiologic concentration, in accordance to the activation of the alpha subunit of 
αLβ2 that presents a divalent cation-binding site (Corbi, Miller et al. 1987). Binding requires also 
metabolic energy, functional cytoskeleton, and it is temperature depending (Marlin and Springer 
1987). 
 
ICAM-1 is a transmembrane heavily glycosylated protein of 532 amino acids. The molecular 
weight mass ranges from 75 to 115 kDa. The different weights reflect different glycosylation and it 
is translated in the ability of binding different ligands. ICAM-1, also known as CD54, presents five 
in tandem immunoglobulin Ig-like domains (Dustin, et al. 1986). ICAM-1 does not contain an RGD 
sequence (Marlin and Springer 1987), ICAM-1 is also a receptor for human rhinoviruses (Table 2) 
(Greve, et al. 1989) (Xing, et al. 2003).  
Soluble intercellular adhesion molecule-1 (sICAM-1) is the circulating form of ICAM-1. There are 
evidences that suggest that sICAM-1 can be a candidate marker of vascular inflammation in 
atherosclerosis and myocardial infarction, although its increased levels were also observed in other 
diseases affecting the cardiovascular system, such as myocarditis, inflammatory cardiomyopathy 
and heart failure per se. 
(Witkowska and Borawska 2004) (Schmidmaier, et al. 2007) (Witkowska 2005). On the other hand, 
loss of cell surface ICAM-1 from the endothelium may serve a protective function where sICAM-1 
acts as a natural inhibitor of αLβ2/ICAM-1 interactions (Zonneveld, et al. 2014). 
ICAM-2 was identified in 1991 by Fougerolles et al. as a second αLβ2 ligand. It showed a different 
and more restricted pattern of distribution compared with ICAM-1. Endothelium and lymphoid cells 
express ICAM-2. ICAM-2, also known as CD102, is as well a transmembrane protein, with a 
molecular weight of 55 – 65 kDa and two IgG like domains (de Fougerolles, et al. 1991). ICAM-2 
is constitutively expressed in contrast to ICAM-1 where the expression is highly inducible (Table 2) 
(Xiao, et al. 2013). 
In 1994 Fougerolles et al. identified ICAM-3 and characterized its interaction with αLβ2 in the 
immune synapse. Both ICAM-2 and ICAM-3 have a similar affinity for αLβ2, however their 
affinities is lower than the affinity of ICAM-1 for αLβ2 ICAM-3, also known as CD50, presents 
five IgG-like domains and a molecular weight of 120 kDa (de Fougerolles and Springer 1992) (de 
Fougerolles, et al. 1994). ICAM-3 shows a pivotal role in the immune synapse and in the generation 
of the immune responses and it is the dominant ligand for αLβ2on resting lymphocytes (Tab. 2) 
(Littler, et al. 1997). 
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ICAM-4 identified in 1940 by Landsteiner and Wiener as part of the human blood group system. It 
has a molecular weight of 40 – 42 kDa and two IgG-like domains (Bloy, et al. 1989). 
In 1994 Bailly et al. aligned the amino sequence of the two IgG like domain of LW protein with the 
sequences of ICAM-1, -2, -3 showing that they are closely related (Bailly, et al. 1994). 
ICAM-4 binds to αLβ2, Mac-1 and αxβ2 (Table 2) (Toivanen, et al. 2008). 
ICAM-5, identified in 1994 by Yoshihara et al., has a molecular weight of 130 kDa and nine 
tandem immunoglobulin-like domains. It also denominated Telencephalin (TLN) because it is 
expressed exclusively in the telencephalon where it displays two types of binding: homophilic, 
between neurons, and heterophilic, between neurons and leukocytes (Table 2) (Yoshihara, et al. 
1994). 
The junctional adhesion molecule A (JAM-A), also known as JAM-1 or F11R interacts with αLβ2 
in the early events of the transendothelial migration. 
It is expressed as a dimer on the surface of epithelial and endothelial cells, and also hematopoietic 
cells, such as leukocytes, platelets, and erythrocytes, and it is present in endothelial and epithelial 
tight junctions of many different tissues (Table 2) (Wojcikiewicz, et al. 2009). 
 
Table 2 
Overview of the αLβ2 ligands and their expression pattern and regulation (Xiao, et al. 2013) (Naik, et al. 2001). 
αLβ2 Ligands Cellular Expression Inducibility 
ICAM-1 
(CD54) 
Leukocytes, epithelial cells, endothelial cells, 
fibroblasts, Sertoli cells, germ cells 
Highly inducible: 
TNFa, IFN-γ, IL-1a, IL-1b, LPS, phorbol ester, shear stress 
(by blood flow) 
ICAM-2 
(CD102) 
Leukocytes, platelets, epithelial cells, 
endothelial cells, Sertoli cells, germ cells 
Non-inducible: 
Down-regulated by TNFα/IL-1β in HUVECs 
ICAM-3 
(CD50) 
Leukocytes 
Inducible: 
TNFα, retinoic acid, on endothelial cells; down-regulated 
by PMA and Ca2+ ionophore 
ICAM-4 
(CD242, LW) 
Erythrocytes Not determined 
ICAM-5 
(TLN) 
Neurons Non-inducible 
JAM-A 
(JAM-1, F11R) 
Leukocytes, platelets, erythrocytes, epithelial 
cells, endothelial cells  TNF-α and IFN-γ 
 
1.5. VLA-4 VCAM-1 Natalizumab  
In 1987 Hemler et al. identified VLA-4 as a new member of the very late antigen (VLA) protein 
family. VLA-4 (CD49/CD29, α4β1, LPAM-2) is a heterodimeric cell surface integrin with a 
molecular weight of 115 kDa. VLA-4 shares the beta 1 subunit with VLA-1, -2, -3, and -5 and the 
α4 chain with the integrin LPAM-1 (α4β7) (Fig. 1) (Hemler, et al. 1987). 
VLA-4 is expressed on peripheral blood B and T cells, thymocytes and monocytes, mast cells, 
macrophages, basophils and eosinophils, but not neutrophils (Hemler, et al. 1990). VCAM-1 and 
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fibronectin are the ligands of VLA-4. VCAM-1 was identified as ligand in 1990 by Elices et al. and 
is a member of the immunoglobulin family. VLA-4 appears to be its major or only receptor (Elices, 
et al. 1990). 
VCAM-1 expression is inducible. Endothelial cells express VCAM-1 in response to cytokines 
produced in the tissue, high levels of ROS, oxidized low density lipoprotein (oxLDL), 25-
hydroxycholesterol, turbulent shear stress, high glucose, and microbial stimulation of endothelial 
cell TLRs. VCAM-1 can also be released in a soluble form, sVCAM, from the endothelial surface 
through cleavage by a metalloprotease. The expression of VCAM-1 in lymph nodes and in the bone 
marrow regulates the homing of leukocyte (Cook-Mills, et al. 2011). 
Antibodies against VCAM-1 can interfere with the formation of lamellopodia in monocytes, 
preventing in this way diapedesis (Ronald, et al. 2001). In 1989 Wayner et al. described VLA-4 as a 
new fibronectin receptor (Wayner, et al. 1989). Fibronectin is a glycoprotein of the extracellular 
matrix (ECM) that plays a role in the interaction between cells and ECM (Pankov and Yamada 
2002). 
The VLA-4/VCAM-1 interaction mediates the tethering, rolling and firm adhesion during an 
inflammatory response (Laberge, et al. 1995). 
The synergistic interaction of VLA-4 and αLβ2 to their respective ligands increase the binding of 
the cells, VCAM-1 binding to VLA-4 results in increased αLβ2-mediated adhesion of T 
lymphocytes to ICAM-1 via an avidity-dependent mechanism (Chan, et al. 2000). 
On the other hand, the occupation of T cell αLβ2 by its ligand ICAM-1 decreases the binding of 
VLA-4 to ligands fibronectin and VCAM-1 (Porter and Hogg 1997). In contrast to αLβ2, VLA-4 
can bind ligands also when it is in its natural resting state. This phenomenon could explain why 
inhibitors against VLA-4 are usually competitive and not allosteric (Chigaev and Sklar 2012). 
VLA-4 is an interesting target for the treatment of several diseases because of the roles it has in 
different inflammatory processes. Peptides, cyclic peptides derived from ligand, small molecule 
inhibitors, and monoclonal antibody are used (Yednock, et al. 1992) (Lin and Castro 1998). 
Firategrast is a small molecule α4 antagonist developed by Glaxo Smith Kline for the treatment of 
relapsing remitting multiple sclerosis. It has entered Phase II clinical trials (Millard, et al. 2011).  
Heparin is a ligand for VLA-4. In the treatment of metastatic cancers, where the cells are positive 
for VLA-4, heparin can be used to target this integrin as inhibitor of cancer progression (Fritzsche, 
et al. 2008) (Schlesinger, et al. 2009) (Chigaev, et al. 2011). 
Regarding monoclonal antibodies, Natalizumab was approved by the FDA in 2004 and is used for 
the treatment of multiple sclerosis and Crohn's disease. Natalizumab is an IgG4k humanized 
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monoclonal antibody, it binds α4 chain of VLA-4, preventing the transmigration of lymphocytes to 
the CNS (Lutterotti and Martin 2008). 
After IV administration of Natalizumab, the IgG4 isotype antibody engages in Fab-arm exchange 
with other IgGs present in the serum. This leads to antibodies that are monovalent (Rispens, et al. 
2011). 
As seen for Efalizumab, treatment with Natalizumab leads to an immunosuppressive state 
associated with progressive multifocal leukoencephalopathy (PML) (Meira, Sievers et al. 2016). 
Natalizumab was first withdrawn from markets in 2005 but then relaunched in the USA and 
European market in 2006 (Lutterotti and Martin 2008) (Benkert, et al. 2012) (Carson, et al. 2009) 
 
1.6. LAD 
Leukocytes adhesion deficiency (LAD) is a rare autosomal recessive disorder characterized by 
immunodeficiency resulting in severe infections. It is caused by deficiency of adhesive 
glycoproteins on the surfaces of white blood cells (WBCs). This results in lymphocytes, monocytes 
and granulocytes with defects in their main functions: adhesion to endothelium, phagocytosis, cell-
mediated cytolysis, and response to specific antigens (Kishimoto, et al. 1987).  
LAD is currently divided into three subtypes: LAD-I, LAD-II and LAD-III.  
LAD-I has been identified in patients having a deficiency in β2 (CD18) integrins. LAD-I is 
characterized by recurring bacterial and fungal infections, impaired wound healing and severe 
gingivitis (Hogg and Bates 2000). 
In the LAD-II syndrome, there is a lack in fucosylated glycoconjugates. In this form of LAD, 
neutrophils fail in binding to E-selectin on IL-1 activated endothelial cells (Karsan, et al. 1998). 
LAD-III is characterized by defective kindlin-3 production and it is associated with Glanzmann-
type bleeding disease. Kindlin-3 deficiency is reported to cause abnormal β integrin activation. 
Defective function of β3 integrin results in platelets that are no capable of binding to each others 
(Robert, et al. 2011). 
 
1.7. Efalizumab 
Efalizumab is a humanized anti-CD11a antibody, the alpha chain of the integrin αLβ2. Efalizumab, 
molecular weight 148,841 Da, is an IgG1k isotype antibody with two identical kappa light chains 
(214 a.a.), and two gamma heavy chains (415 a.a.). Each light chain is linked by disulphide bridge 
to a heavy chain. The two heavy chains are linked together by disulphide bridge. 
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Efalizumab was developed as a murine anti-CD11a monoclonal antibody MHM24 (Hildreth and 
August 1985), and prepared by replacing mouse DNA sequences with human DNA sequences 
(Boehncke 2007a). 
The specificity of efalizumab is restricted to human and chimpanzee CD11a (Champe, et al. 1995) 
(Reimann, et al. 1994).  
M17, a rat IgG2a anti-mouse CD11a monoclonal antibody, shows pharmacological activities that 
are similar to efalizumab (Nakakura, et al. 1993). Both M17 and Efalizumab bind to the I domain 
region of the CD11a inhibiting the interaction of αLβ2 with ICAM. The epitope for M17 is within 
the ICAM binding region, in contrast the epitope for efalizumab is outside the ICAM binding 
region. 
Administration of M17 to mice results in the development of anti-M17 antibodies, for this reason a 
rat-mouse chimera construct, muM17, was prepared to reduce and overcome the immunogenicity of 
M17 (Clarke, et al. 2004). 
The Fc part of efalizumab is recognised by the Fcγ receptor series (FcγRI, FcγRIIA, FcγRIIB and 
FcγRIIIA). Efalizumab does not show complement-dependent cytotoxicity (CDC), binding poorly 
to the complement protein C1q (Chetty, et al. 2014) (Brennan, et al. 2010). 
Efalizumab inhibits the binding of αLβ2 to ICAM-1, -2, and -3 (Boehncke 2007a), and it is also 
able to inhibit the mixed lymphocyte response, T cell activation, T-lymphocyte adhesion to human 
endothelial cells, and trans-endothelial T cell migration (Boehncke 2007b) (Clarke, et al. 2004). 
Efalizumab interacts with the alpha I domain, it blocks the binding of ICAM-1 to αLβ2 via steric 
hindrance. The Fab light chain has spatial conflicts with the domain 2 of ICAM-1 (Li, et al. 2009). 
After binding to αLβ2, efalizumab is internalized by T cells, translocated to lysosomes and 
degraded in complex with αLβ2. This process constitutes one of the pathways for in vivo clearance 
of efalizumab (Coffey, et al. 2005). 
Efalizumab acts as immunosuppressant, inducing T cell hyporesponsiveness. CD3- and CD2-
mediated activation is reduced after treatment with efalizumab, (Guttman-Yassky, et al. 2008) 
(Major 2010). 
In patients the administration of efalizumab leads to the downmodulation of several others surface 
molecules like CD3, TCR, CD4, CD8, CD28, and the integrin VLA-4 (Guttman-Yassky, et al. 
2008) (Major 2010) (Boehncke 2007a). 
Efalizumab was commercialized with the name of Raptiva® by Genentech. It was indicated for the 
treatment of moderate to severe chronic plaque psoriasis where it was able to alleviate signs and 
symptoms of the disease by inhibiting T-lymphocyte activation in lymph nodes, T-lymphocyte 
trafficking into psoriatic lesions, T-lymphocyte interaction with keratinocytes, secondary activation 
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of T-lymphocytes in plaques, and release of pro-inflammatory cytokines (Boehncke 2007a). 
Raptiva was approved by FDA in 2003 and by EMEA in 2004. In 2009 the antibody was withdrawn 
from markets because benefits of efalizumab did not outweigh the risks of PML or other serious 
infections (Carson, et al. 2009). 
 
1.8. Progressive multifocal leukoencephalopathy - PML 
PML is a demyelinating disease of the white matter of the human brain caused by the reactivation 
of latent JC virus, a virus that leads to a lytic infection of oligodendrocytes. It occurs mainly in 
immune-suppressed patients.  
Its highest incidence is in AIDS patients, ∼3% of HIV-1-infected individuals. In addition to severe 
immune suppression, there appear to be synergistic interactions between HIV-1 and JCV that 
contribute to the higher incidence of PML in AIDS patients (Tyler 2010).  
People on chronic immunosuppressive medications, including chemotherapy, are also at increased 
risk of PML, such as patients with transplants, Hodgkin's Lymphoma, multiple sclerosis, psoriasis 
and other autoimmune diseases.  
Concerning anti-VLA-4 mAb natalizumab, in 2005 it was voluntarily withdrawn from the market 
because it was linked with three lethal cases of PML (Yousry, et al. 2006). The risk of PML was 
assessed about 1.0 case per 1,000 patients treated over 18 months, with a possible increased risk in 
case of additional time treatment (Yousry, et al. 2006). To date, natalizumab is back to the market 
but the treatment is under a restrictive risk management program (Nijsten, et al. 2009). 
In 2009, before the anti-αLβ2 efalizumab was withdrawn, Genentech provided and updated about 
safety findings with the “U.S. BL 125075/130 Amendment: Efalizumab-Genentech, Inc.” 
 
WARNING:  
RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML):  
• RAPTIVA increases the risk for PML, a rapidly progressive viral infection of the central nervous 
system that has no known treatment and that leads to death or severe disability. The risk of PML may 
markedly increase with longer duration of RAPTIVA exposure. The time dependent threshold when 
the risk for PML increases is unknown (see WARNINGS).  
 
o Patients on RAPTIVA should be monitored frequently to ensure they are receiving 
significant clinical benefit, to ensure they understand the significance of the risk of 
PML, and for any sign or symptom that may be suggestive of PML (see 
WARNINGS).  
o RAPTIVA dosing should be withheld immediately at the first sign or symptom 
suggestive of PML. For diagnosis, brain magnetic resonance imaging (MRI) and, 
when indicated, cerebrospinal fluid analyses for JC viral DNA are recommended (see 
WARNINGS).  
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RISK OF SERIOUS INFECTIONS  
• Infections, including serious infections leading to hospitalizations or death, have been observed in 
patients treated with RAPTIVA (see WARNINGS and ADVERSE REACTIONS). These infections 
have included bacterial sepsis, viral meningitis, invasive fungal disease and other opportunistic 
infections. Patients should be educated about the symptoms of infection and be closely monitored for 
signs and symptoms of infection during and after treatment with RAPTIVA. If a patient develops a 
serious infection, RAPTIVA should be discontinued and appropriate therapy instituted. 
 
The incidence of PML in patients treated with efalizumab is estimated to be 1 case per 15,000 
person years (Nijsten, et al. 2009). The link between the effects of monoclonal antibody treatments 
that target proteins of the immune system, adhesion proteins or cell surface markers (Efalizumab- 
αLβ2, Natalizumab-VLA-4 and Rituximab-CD20) and the occurrence of PML could be explained 
by the latency of JCV in the bone marrow. Under therapy, bone marrow derived cell carrying latent 
virus may be released into the circulation and may enter the brain (Seminara and Gelfand 2010). 
 
1.9. Small Molecule αLβ2 inhibitors 
Several small molecule inhibitors have been described in patent applications or scientific literature 
which affect the interaction of αLβ2 with their ligands (Giblin and Lemieux 2006). To date, these 
compounds can be grouped into two major classes, based on how they bind to αLβ2 and how they 
influence αLβ2 conformation. One class of inhibitors, termed alpha I allosteric inhibitors, binds to 
the ligand binding domain (termed I domain) on the αLβ2 alpha chain, however at a site distal to 
the ligand binding site (termed αL I allosteric site). These inhibitors stabilize αLβ2 in its bent 
inactive state, preventing the switchblade-like opening of αLβ2 into its extended active state, and 
the exposure of activation epitopes (Giblin and Lemieux 2006). Furthermore, the binding of alpha I 
allosteric inhibitors to αLβ2 can be elegantly detected by the loss of the mAb R7.1 epitope (Weitz-
Schmidt, et al. 2004). Major chemical classes of alpha I allosteric inhibitors which have been 
described so far include hydantoin derivatives, statin (or “mevinolin”)-based derivatives, substituted 
diazepanes and arylthio cinnamide analogues (Giblin and Lemieux 2006) (Kapp, et al. 2013). None 
of these compounds is reported to be in clinical development, currently.  
Another group of inhibitors, termed α/β I allosteric inhibitors, are ligand mimetics, i.e. they are 
derived from amino acids of the αLβ2 binding region of ICAM (Giblin and Lemieux 2006) (Kapp, 
et al. 2013). Unexpectedly, these ligand mimetics do not bind to the ligand binding site of αLβ2 
located on the alpha chain. Instead, they act via the αLβ2 beta chain by competing with the 
interaction of an internal ligand. As a result, the binding domain of αLβ2 remains in a low affinity 
state whereas the rest of αLβ2 adapts an extended, active conformation, exposing activation 
epitopes (Giblin and Lemieux 2006). Cells treated with these inhibitors exhibit paradoxical 
activities, i.e. induction of “rolling adhesion” by the inhibitors, in contrast to cells treated with αL I 
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allosteric inhibitors (Salas, et al. 2004). Paradoxical agonism has also been observed with ligand 
mimetics targeting other integrin family members including αIIbβ3 (Ahrens and Peter 2008). 
Currently, one ligand mimetic αLβ2 was approved by FDA for the treatment of the signs and 
symptoms of dry eye disease (DED) (Sheppard, et al. 2014) (Kapp, et al. 2013) (Holland, et al. 
2016). 
 
1.10. Lifitegrast  
Lifitegrast is a small molecule peptidomimetic (615.48 Da) which binds to the integrin αLβ2 
preventing this integrin from interacting with ICAM-1 (Fig. 6) (Zhong, et al. 2012). It belongs to 
the class of α/β I allosteric αLβ2 inhibitors. 
 
 
Fig. 6. Lifitegrast 
 
Lifitegrast has been developed by Shire as a treatment for DED.  
ICAM-1 is overexpressed in the tissue of the cornea and conjunctiva in DED, and the interaction 
between ICAM-1 and αLβ2promotes lymphocyte activation and migration and accumulation into 
the ocular surface (Gao, et al. 2004).  
In a Phase II trial, conducted on a total of 230 patients with dry eye, lifitegrast showed a significant 
improvement in corneal staining score and visual related function and improvements in tear 
production (Semba, et al. 2012). In a Phase III, trial conducted on 718 patients with dry eye disease, 
lifitegrast was administered as eye drops (5% solution) or placebo twice a day for 12 weeks, after a 
14-day open label placebo run-in period. Lifitegrast showed improvement in eye dryness compared 
to placebo-treated subjects with significant improvement of secondary symptom end points (Tauber, 
et al. 2015). In July 2016, lifitegrast was approved by FDA for the treatment of the signs and 
symptoms of DED (Holland, et al. 2016). 
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1.11. XVA143 
XVA143, a peptidomimetic αLβ2 inhibitor (Fig. 7), with an α/β I-like allosteric inhibitor of αLβ2. 
XVA143 is not selective for αLβ2, it also inhibits other β2 integrins including Mac-1 (Welzenbach, 
et al. 2002). 
 
 
Fig. 7. XVA143. 
 
The binding of XVA143 to the β2 MIDAS blocks the interaction of the β2 MIDAS domain itself 
with the αL-Glu-310. This amino acid is located on the C-linker, which follows the α7-helix at the 
C-terminal end of the α I domain and it binds to the MIDAS of the active I domain. Glu-310 can be 
considered an intrinsic ligand for αLβ2. This interaction leads to downward displacement of the α7 
helix, turning the α I MIDAS into a high-affinity, ligand-binding state (Weitz-Schmidt, et al. 2011). 
XVA143 binds to the β I domain MIDAS and blocks α I activation by preventing the binding of the 
intrinsic β2 MIDAS ligand αL-E310 (Schurpf and Springer 2011) (Yang, et al. 2006). 
XVA143 blocks α I activation by disrupting signal transmission between the α I and β I-like 
domains (Yang, et al. 2004) and in the same time induces the extension of αLβ2 leading to rolling 
of the cells (Salas, et al. 2004) (Chigaev, et al. 2015). The induction of the β2 leg extension 
(Schurpf and Springer 2011) leads to the exposure of KIM127 mAb epitope in the I-EGF-2 domain 
(Chigaev, et al. 2015) (Nishida, et al. 2006).  
XVA143 can also inhibit the homotypic adhesion of NK cells and induce the disaggregation of NK 
cells (Chen, et al. 2010). 
In K562 cells, XVA143 not only extends αLβ2 but also stabilizes the extended low- or 
intermediate-affinity bonds with ICAM-1 (Feigelson, et al. 2010). 
αLβ2 antagonists, interfering with cell-to-cell contact, can affect viral propagation events. XVA143 
could inhibit HIV-1 replication, opening to a potential use of this kind of antagonists in 
combination with traditional therapy (Tardif, et al. 2009). 
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1.12. LFA878 
LFA878 is a statin-derived small compound (MW 596.77) (Fig. 8).  
 
 
Fig. 8. LFA878. 
 
It binds the α I domain of αLβ2 inhibiting allosterically the binding of αLβ2 to its ligands (Fig. 9). 
LFA878 lacks the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase activity. LFA878 has 
strong anti-inflammatory properties in first place for its direct effect on αLβ2 and then because this 
results in impaired T cell costimulation (Weitz-Schmidt, et al. 2004). 
 
 
Fig. 9. X-ray structure of αLβ2 I domain in 
complex with LFA878 at 2.1A resolution. 
http://www.rcsb.org/pdb/explore/jmol.do?stru
ctureId=1XDG&bionumber=1 
 
Studies show that LFA878 could also induce cell death in several multiple myeloma cell lines by 
apoptosis, through the caspase 3 pathway and redistribution of negatively charged phospholipids 
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transported to the outer cell surface. The induction of apoptosis has not been seen in PBMCs 
suggesting a disease specific effect (Schmidmaier, et al. 2007). This property was already shown for 
simvastatin, the statin with the most potent antimyeloma activity (Schmidmaier, et al. 2006). 
LFA878 can also target the harmful effects of NK cells, preventing their homotypic adhesion and 
promoting the disaggregation of existing NK cell clusters (Weitz-Schmidt, et al. 2009). 
X-ray crystallography clarified the molecular basis of the binding to the I domain and allowed the 
design of potent and selective small molecule inhibitors of αLβ2. 
The engagement and the inhibition of αLβ2 by LFA878 through binging of the I domain can be 
detected in undiluted human blood, that permits to study the role of the I domain under 
physiological conditions (Weitz-Schmidt, et al. 2001) (Weitz-Schmidt, et al. 2004). 
 
Taken together, it is appreciated that αLβ2 is a receptor involved in inflammatory, immune-
mediated and infectious diseases and is overexpressed in certain malignant diseases. These diseases 
are often severe, chronic disorders often requiring life-long therapy. From a clinical perspective, 
there remains a high need for effective therapies either preventing the conditions or controlling the 
activity of disease and providing long-term benefit/risk profiles superior to currently available 
therapies. It is further appreciated that novel αLβ2 inhibitors with improved pharmacologic profiles 
and devoid of side effects observed with earlier αLβ2 inhibitors will constitute a therapeutic 
advance. 
In conclusion, based on the status of prior art, there remains a need for novel, improved αLβ2 
inhibitors of chemical scaffolds different to scaffolds described before. The availability of such 
inhibitors would provide additional therapeutic and diagnostic options across the spectrum of 
diseases in which αLβ2 is involved or can be employed as a target for drug delivery, given that 
different chemical structures will be associated with different pharmacologic profiles. 
Furthermore, it is appreciated that the function of αLβ2 can be modulated in different ways and that 
unwanted effects/side-effects observed with certain classes of existing αLβ2 inhibitors, such as anti- 
αLβ2 monoclonal antibodies, may not be observed with novel types of αLβ2 inhibitors. 
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From virtual screening to highly potent, orally available small molecule 
inhibitors of the integrin aLb2 
 
Abbreviations: ADMIDAS, adjacent to metal ion-dependent adhesion site; AK, adenylate kinase; 
AUC, area under the curve; AUCINF, area under the curve from time zero to infinity; BCECF-AM, 
2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester; BSA, bovine serum 
albumin, CADD, computer-aided drug discovery; CD, cluster of differentiation; CLF, formation 
clearance of a drug to a metabolite; Cmax, maximum plasma concentration; CV, coefficient of 
variation; DMSO, dimethyl sulfoxide; EDTA, ethylenediaminetetraacetic acid; Fc, fragment 
crystallizable; FCS, foetal calf serum; FITC, fluorescein isothiocyanate; FSC, forward scatter; 
IC50, half maximal inhibitory concentration; ICAM, intercellular adhesion molecules; IgG-x, 
immunoglobulin G cross-linked; IgG, immunoglobulin G; IL, interleukin; IS, immunological 
synapse; IS, internal standard; LFA-1, lymphocyte function-associated antigen-1; LPS, 
lipopolysaccharide; mAb, monoclonal antibody; MFI, mean fluorescence intensities; MHC, major 
histocompatibility complex; OD, optical density; pAb, polyclonal antibody; PAM, point accepted 
mutation; PBMC, peripheral blood mononuclear cell; PD, pharmakodynamic; PE, phycoerythrin; 
PI, propidium iodide; PK, pharmacokinetic; PMA, phorbol 12-myristate 13-acetate; po, per os; 
Rsq, square of correlation coefficient; S/N, signal to noise ratio; SAR, structure activity 
relationship; SD, standard deviation; SSC, side scatter; t1/2, elimination half-life; TCR, T cell 
receptor; tmax, time to reach maximum concentration; VCAM-1, vascular cell adhesion protein-1; 
VCAM, vascular cell adhesion molecule; VLA-4, very late antigen-4; VzF, apparent volume of 
distribution during terminal phase after non-intravenous administration; ZAP70, zeta-chain-
associated protein kinase 70; 
 
Abstract 
The integrin lymphocyte function-associated antigen-1 (LFA-1, aLb2) is expressed on all 
leukocytes. The interaction between aLb2 and the intercellular adhesion molecules (ICAMs) is 
pivotal in cell adhesion, leukocyte trafficking, T cell costimulation and immunological synapse (IS) 
formation. aLb2 is centrally involved in immune-mediated diseases of high medical need. 
Here we describe the identification, synthesis, in vitro structure-activity relationship (SAR) and 
preclinical characterization of innovative a I allosteric inhibitors that modulate aLb2 function via 
binding to the αL I allosteric site. Virtual screening has been used to identify a new chemical 
scaffold that modulates aLb2 function. Optimization of this scaffold has resulted in high-affinity 
inhibitors of the aLb2/ICAM-1 interaction, with IC50 values in the low nM range. A selected lead 
compound has been transitioned to preclinical pharmacokinetic (PK) characterization in vivo. This 
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new class of inhibitors is expected to overcome major unwanted effects of current integrin targeting 
drugs.  
 
1. Introduction 
The integrin aLb2 is expressed on leukocytes. In its activated state aLb2 mediates the adhesion of 
leukocytes to each other and to other cells regulating leukocyte trafficking, T cell costimulation and 
immunological synapse (IS) formation (Hogg, et al. 2011). 
In its inactive, bent state, aLb2 is not capable to mediate cell adhesion and to induce signalling. 
Upon activation from inside the cell (inside-out signalling) aLb2 converts into an activated 
extended state which is able to bind its ligands, intercellular adhesion molecules (ICAMs), to 
mediate adhesion and induce signalling (outside-in signalling) (Hogg, et al. 2011). 
aLb2 is centrally involved in immune-mediated diseases of high medical need, including chronic 
plaque psoriasis, multiple sclerosis, rheumatoid arthritis, small vessel vasculitis, dry eye disease and 
transplantation indications, among other disorders. In several of these diseases, aLb2 has been 
validated by biologic therapies as a target of high therapeutic potential (Millard, et al. 2011) 
(Shimaoka and Springer 2003) (Cox, et al. 2010b).  
From a pharmacological perspective, the stabilization of the inactive (bent) state of aLb2 by low 
molecular weight compounds constitutes the most elegant approach to therapeutically modulate its 
function. This approach is also expected to overcome major limitations of current ligand mimetics 
and biologics targeting integrins. For example, it is anticipated that pharmacological stabilizing of 
the inactive form of integrins will avoid unwanted agonist-like effects such as the gross 
downmodulation of major immune receptors (also termed transmodulation) as observed for the anti-
aLb2 mAb efalizumab (Guttman-Yassky, et al. 2008) or paradoxical agonism as observed for 
various ligand mimetics targeting integrins (Jones, et al. 2010) (Millard, et al. 2011) (Salas, et al. 
2004) (Schurpf and Springer 2011). 
Previous studies indicate that low molecular weight allosteric modulators of aLb2, targeting the αL 
I allosteric site, are able to stabilize aLb2 in its inactive state and may thereby avoid 
transmodulation and/or paradoxical agonism. Indeed, we recently demonstrated that inhibitors 
belonging to the αL I allosteric class can be clearly differentiated from anti-aLb2 mAbs (i.e. 
efalizumab) and aLb2 targeting a/b I allosteric inhibitors in terms of their downstream effects on 
aLb2 (Mancuso, et al.2016). Several small molecules which bind to the I allosteric site of aLb2 
have been characterized extensively (Giblin and Lemieux 2006) (Fig. 1) however, none of these 
compounds meet the pharmacological requirements that would permit their full development into 
systemically used drugs, i.e. they either provide inadequate pharmacokinetic characteristics and/or 
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are associated with systemic safety concerns attributable to their chemical scaffold (Cox, et al. 
2010a) (Goodman and Picard 2012) (Miller, et al. 2009). As a consequence, currently there is no 
aLb2 modulator with the intended mode of action on the market. 
In collaboration with Gisbert Schneider’s group at the ETH Zürich we used a virtual screening 
approach for the identification of a novel class of aL I allosteric aLb2 modulators.  
 
 
Fig. 1. Close-up view of the aL I domain allosteric site within the aLb2 I domain. Indicated in green, red, 
blue and yellow are the residues of the I allosteric site that are located in close proximity of 4 different 
classes of alpha I allosteric inhibitors (Source: Giblin and Lemieux 2006). 
 
Three million drug-like, commercially available compounds have been screened and candidates for 
aLb2 activity testing prioritized, taking known low molecular weight inhibitors as queries for 
multiple similarity searches and compound ranking.  
This virtual screen yielded in ranked lists of compounds. Resulting lists have been combined and 
analyzed (“data fusion”). Off-targets and potential liabilities of the hits found have been addressed 
in silico by extensive comparison to a set of 672 drug targets using proprietary algorithms for target 
profile prediction. As the outcome of the first virtual screening triage, approximately 200 
commercially available candidate compounds have been submitted for biochemical activity 
determination. 60 commercially available compounds were purchased.  
 
 
Here we describe the analysis of these selected 60 compounds, the identification of a hit compound 
and the chemical derivatization of this hit towards potent lead compounds (collaborative work with 
Marianne Hürzeler’s group at the School of Life Sciences, FHNW Basel) and the detailed 
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characterisation of the most advanced inhibitor including first pharmacokinetic properties of the 
compound in rats. 
 
2. Materials and Methods  
 
2.1. Synthesis of chemical compounds 
Chemical reagents and solvents were purchased from commercial sources (Sigma-Aldrich, St. 
Louis, MO, and Bachem, Bubendorf, CH). 
The compounds were prepared by the exemplary processes described in detail in the following 
reaction schemes.  
 
Methods of Scheme A. To a solution of anhydride 1 (1 eq.) in acetic acid amine (1 eq.) was added 
and the reaction mixture was boiled for 2–10 h. Then the solvent was removed at reduced pressure. 
The residue was dissolved in DCM and washed with sat. aq. NaHCO3, aq. 1N HCl and sat. aq. 
NaCl, dried over Na2SO4 and the solvent was removed at reduced pressure. The crude product was 
purified by silica gel flash chromatography (Shults, et al. 2005). To a solution of maleimide 2 (1 
eq.) in DCM or toluene a solution of diazo compound in DCM or toluene was added. The mixture 
was stirred at room temperature (rt) for 2-10 days until the disappearance of the diazo colour. The 
precipitate was filtered off and washed with ethanol (Molchanov, et al. 2002). In cases without a 
precipitate, the solution was used directly in the next step. A mixture of pyrazoline-intermediate 3 
and toluene was heated to 100 °C for 1-2 h at 100 °C. The solvent was removed at reduced pressure 
and the crude product purified by silica gel flash chromatography (Molchanov, et al. 2002). 
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Methods of Scheme B. To the hydrazone 8 (1 eq.) in DCM MnO2 was added. The suspension was 
stirred for 15 min at rt and then filtered. The purple solution of 5 was used directly in the next step 
(Bourget, et al. 2005). 
To a stirred suspension of 4-toluenesulfonohydrazide (1 eq.) and MeOH the aldehyde or ketone 6 (1 
eq.) was added. After 1-14 h stirring at different temperatures (rt until 60 °C) the reaction was 
complete. The suspension was filtered or centrifuged, and then washed with small amounts of 
MeOH to afford solid 7 (Aggarwal, et al. 2003). 
The hydrazone 7 (1 eq.) and TEBAC (0.25 eq.) was stirred in aq. NaOH (15%, 10 eq.) and toluene 
under nitrogen. After 1-2 h of strong stirring at 70 °C the reaction was usually complete. The deep 
red/purple organic layer was washed with sat. aq. NH4Cl, sat. aq. NaCl and dried with Na2SO4. This 
solution of 5 was used directly in the next step (Zhou, et al. 2009). To a solution of the ester 9 (1 
eq.) and p-ABSA (1.5 eq.) in 10 mL dry CH3CN at 0 °C DBU (1.5 eq.) was added over 30 min. 
After stirring for 1 h at rt, the mixture was partitioned between water and EtOAc. The combined 
organic extract was dried and concentrated. The residue was purified by silica gel flash 
chromatography to afford 5 (Taber, et al. 2005). 
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Method of Scheme C. To the substituted bromobenzene (1 eq.) in THF at -78 °C n-BuLi (2.5 M in 
hexane, 1 eq.) was added dropwise and the mixture was stirred at -78 °C for 1 h. To the solution of 
substituted phenyllithium in ether (1 eq.) benzonitrile (1 eq.) in ether was added at 0 °C and the 
mixture was stirred at rt overnight. The reaction mixture was poured onto ice (in some cases 
acidified). The resulting mixture was allowed to warm to rt and was then extracted with ether, dried 
and concentrated at reduced pressure. The crude product was purified by chromatography on 
alumina (Cook and Wakefield 1980). 
 
 
2.2. Preparation of compounds, control compounds and efalizumab 
Test compounds were dissolved at 10 mM in DMSO. Control reagents simvastatin, Triton™ X-100, 
staurosporine, cyclosporine A, amiodarone, procymidone, LPS, PMA and ionomycin were 
purchased from Sigma-Aldrich, St. Louis, MO, and dissolved at 10 mM in DMSO. Compound 
RO0505376 was kindly provided by Dr. Paul Gillespie. For the experiments, the compounds were 
serially pre-diluted in DMSO to avoid precipitation followed by dilution in medium or assay buffer. 
Final DMSO concentration during the experiments was ≤ 1%. No cytotoxicity was detected at this 
concentration. Efalizumab (obtained from Merck-Serono when product was on the market) was 
kept at -80 °C in RPMI 1640 at a concentration of 10 mg/ml. Serial dilutions were prepared in 
medium or assay buffer. 
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2.3. Cell Culture 
The human lymphoblastoid cell line Jurkat (European Collection of Cell Cultures, Salisbury, UK), 
the mouse ovalbumin-specific T cell receptor (TCR)-transgenic cell line OT-1 (gift from Ed Palmer, 
University Hospital, Basel, CH), the human monocytic cell line THP-1 (gift from Prof. Dr. Jürg 
Schwaller, University Hospital, Basel, CH) and the human liver cancer cell line HepG2 (ATCC, 
Manassas, VA) were maintained in a humidified incubator at 37 °C supplied with 5% CO2. Jurkat 
cells and THP-1 cells were cultured in RPMI 1640 containing 10% (v/v) heat-inactivated foetal calf 
serum (FCS), 1% MEM amino acids, amphotericin B 1 µg/ml, gentamycin 10 µg/ml (Gibco Life 
Technologies, Paisley, UK). OT-1 cells were cultured in RPMI 1640 containing 5% (v/v) heat-
inactivated FCS, L-glutamine 2 mM, penicillin 100 U/ml and streptomycin 100 µg/ml (Gibco Life 
Technologies, Paisley, UK). HepG2 cells were maintained in DMEM containing 10% (v/v) heat-
inactivated FCS, 1g/l glucose, 4 mM L-glutamine, 2 mM GlutaMax, 1 mM pyruvate, 10 mM 
HEPES buffer, 10 mM non-essential amino acid, penicillin 100 U/ml and streptomycin 100 µg/ml 
(Gibco Life Technologies, Paisley, UK). The density of the cells was maintained below 1 x 106 
cells/ml. Every second or third month, the cell cultures were replaced by a new batch of cells with a 
low passage number.  
 
2.4. Isolation of peripheral blood mononuclear cells (PBMCs) 
PBMCs were isolated from EDTA-blood samples via centrifugation in Ficoll-PaqueTM PLUS 
separating solution according to the manufacturer’s protocol (GE Healthcare, Glattbrugg, CH). The 
blood samples were obtained from healthy donors from the Blood Center SRK of Basel. 
 
2.5. V well adhesion assay ICAM-1 VCAM-1 mICAM-1 
The Jurkat/ICAM-1 (human aLb2 dependent cell adhesion), Jurkat/VCAM-1 (human VLA-4 
dependent cell adhesion) and OT-1/ICAM-1 (murine aLb2 dependent cell adhesion) assays were 
performed in V-bottom 96-well plates (Sigma-Aldrich, St. Louis, MO) as previously described 
(Weetall, et al. 2001) (Weitz-Schmidt and Chreng 2012). Briefly, V bottom plates (Sigma-Aldrich, 
St. Louis, MO) were coated with anti-human IgG mAb (Sigma-Aldrich, St. Louis, MO) diluted in 
coating buffer (20 mM Tris containing 150 mM NaCl, pH 8) (1 µg/ml) and incubated overnight at 4 
°C. The plates were blocked with blocking buffer (50 mM Tris base, 150 mM NaCl, 1.5% BSA 
(w/v), pH 7.2) at 37 °C for 90 minutes (min). Human ICAM-1/Fc chimera, human VCAM-1/Fc 
chimera or mouse ICAM-1/Fc chimera (R&D Systems, Abingdon, UK) were immobilized at 0.3 
µg/ml in coating buffer. For studies with efalizumab, human ICAM-1 without Fc-tag (R&D 
Systems, Abingdon, UK) was directly immobilized to V bottom plates without capturing mAb. The 
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plates were incubated at 37 °C for 90 min and washed with binding buffer (50 mM Tris base, 150 
mM NaCl, 1.5% BSA (w/v), 2 mM MgCl2, 2 mM MnCl2, 5 mM D-glucose monohydrate, pH 7.2- 
7.4). The cells were fluorescently labelled with 1 µg/ml of BCECF-AM (Gibco Life Technologies, 
Paisley, UK) in PBS at 37 °C for 20 min and washed with PBS. The labelled Jurkat cells or OT-1 
cells were resuspended in binding buffer and test compounds or solvent controls were added. After 
40 min at 37 °C 30,000 cells/well were transferred to the integrin ligand coated V well plates. After 
5 min of incubation at rt plates were centrifuged for 4 min at 1,000 rpm using the Centrifuge 
Eppendorf 10 5810 R (Eppendorf, Schönenbuch, CH), without activating the brake. Non-adherent 
cells accumulated in the centre of the V-bottom and were quantified using the fluorescence reader 
Tecan M200 Pro Infinity (Tecan, Mannedorf, CH) (excitation 485 nm / emission at 535 nm). The 
half maximal inhibitory concentration (IC50) values were calculated using the software GraphPad 
Prism 6 (GraphPad Software, La Jolla, CA). 
 
2.6. Quantification of mAb R7.1, MEM148 or m24 binding to aLb2 
Conformational changes of aLb2 upon inhibitor binding were quantified using FITC-labelled anti-
aLb2 mAb R7.1 (ebioscience, Frankfurt, D), PE-labelled anti-aLb2 mAb MEM148 (Sigma-
Aldrich, St. Louis, MO) and Alexa Fluor® 488-labelled anti-aLb2 mAb m24 (Biolegend, San 
Diego, CA). For mAb R7.1 binding, Jurkat cells were resuspended in assay buffer (50 mM Tris, 
150 mM NaCl, 2 mM MgCl2, 1.5% BSA and 10 mM D-glucose monohydrate, pH 7.2. For mAb 
MEM148 and m24 binding, 50 mM Tris, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM 
Glucose, 1.5% BSA, pH 7.3). Jurkat cells were transferred in their respective assay buffer to 
polypropylene tubes containing the compounds, efalizumab, efalizumab cross-linked (efalizumab-x) 
or respective solvent and IgG controls (Sigma-Aldrich, St. Louis, MO). Multimeric/cross-linked 
efalizumab was generated by incubation of efalizumab with a goat anti-human IgG (Sigma-Aldrich, 
St. Louis, MO) at a ratio of 1:1 (10 µg/ml) in assay buffer. The cells were pre-incubated with the 
compounds at 37 °C for 40 min. In experiments in which the effect of the compounds and the 
antibody on MnCl2-induced MEM148 or m24 epitope exposure was studied, cells were pre-
incubated in assay buffer containing the inhibitors and the respective controls at 37 °C for 30 min. 
Then MnCl2 was added to a final concentration of 2 mM, followed by an incubation of 30 min at 37 
°C. After this incubation, the cell suspension was centrifuged, the supernatant discarded. Cells were 
stained with mAb R7.1 on ice or with mAb MEM148 and mAb m24 at 37 °C for 30 min, 
respectively (final concentration mAbs 1 - 2 µg/ml). After two wash cycles cells were analyzed by 
flow cytometry using a FACScalibur (BD, East Rutherford, NJ). Mean fluorescence intensities 
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(MFI) of FSC/SSC gated events were calculated using the FlowJo software 10.0.8 (Tree Star, 
Ashland, OR). 
 
2.7. Quantification of mAb R7.1 binding to aLb2 in whole blood of different species 
Conformational change of aLb2 upon inhibitor binding was also quantified in whole blood of 
human, rabbit, mouse and pig using FITC-labelled anti-aLb2 mAb R7.1 (ebioscience, Frankfurt, 
D). The human blood samples were obtained from healthy donors from the Blood Center SRK of 
Basel. The mouse blood samples (Mus musculus) were obtained from the animal facility of the 
Department of Biomedicine, Basel. The rabbit blood samples (Oryctolagus cuniculus) were kindly 
provided by Prof. Dr. Ivan Martin, University Hospital Basel. The porcine blood samples (Sus 
scrofa) were kindly provided by Dr. Michele Diana, Hôpital Universitaire de Strasbourg. Blood 
aliquots (100 µl) were mixed with the compound solution or DMSO (0.3 µl) and incubated for 40 
min at rt. After this incubation, cells were stained with mAb R7.1 at rt for 30 min. Erythrocytes 
were then lysed with FACS lysing solution (BD Biosciences, Switzerland). Samples were 
centrifuged at 200 x g for 5 min and pellets were washed two times in PBS and resuspended in 100 
µl of PBS. Cells were analyzed by flow cytometry using a FACScalibur (BD, East Rutherford, NJ). 
Mean fluorescence intensities (MFI) of FSC/SSC gated events were calculated using the FlowJo 
software 10.0.8 (Tree Star, Ashland, OR). 
 
2.8. Cytotoxicity and apoptosis  
Cytotoxicity was investigated in Jurkat and HepG2 cells using the ToxiLightTM BioAssay Kit 
(Lonza, Basel, CH), measuring the release of adenylate kinase (AK), a marker for loss of cell 
membrane integrity, and CellTiter-Glo® Luminescent Cell Viability Assay, determining the 
number of viable cells in culture based on quantitation of the ATP present, an indicator of 
metabolically active cells. After 24 h incubation with compounds, or controls, toxicity and viability 
were determined by plate reader measurements following manufacturer’s instructions. 
Apoptosis and secondary necrosis were determined by flow cytometry after 24 h incubation with 
compounds or controls, using Annexin V and propidium iodide (PI) staining kit and following 
manufacturer’s instructions (Vybrant TM Apoptosis Assay Kit #2, Gibco Life Technologies, 
Paisley, UK). 
 
2.9. Cytokine release 
IL-6 cytokine concentration was determined by ELISA commercial kit (Biolegend, San Diego, 
CA); detection limit was 7.8 pg/ml. 50,000 THP-1 cells/well were incubated in 96 well plate in 
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presence of testing compounds, efalizumab or controls. After 24 h, supernatant was collected and 
protein concentration was measured by BCA assay.  
Nunc Maxisorp™ 96 MicroWell plates were coated with capture antibody and the plates were then 
incubated at 4 °C overnight. After four washes with PBS pH 7.4 containing 0.05% Tween 20 
(washing buffer), nonspecific binding sites were blocked by incubation for 1 h at rt in assay diluent 
A with shaking at 200 rpm on a plate shaker. After four washes with washing buffer, supernatants 
or standards diluted in assay diluent A were added. All the samples were in duplicate. Following 
incubation at rt for 2 h with shaking, and then four washes with washing buffer. 
IL-6 was detected with a specific antibody against it. The bound anti-IL-6 antibody was detected 
with biotinylated-conjugated anti-human IgG by incubation at rt for 1 h with shaking, followed by 
four washes with washing buffer. An avidin-HRP solution was added to each well and the plate 
incubated at rt for 30 min with shaking followed by five washes. 
100 µl of 1:1 TMB Reagent A and TMB Reagent B solution were added to each well and the plate 
was incubated at rt for 30 min for colour development. To stop the colour reaction, 100 µl of TMB 
Stop solution were added. The optical density (OD) was quantified using the fluorescence reader 
Tecan M200 Pro Infinity (Tecan, Mannedorf, CH) set to 450 nm. 
 
2.10. Analysis of aLb2 expression and internalization 
PBMCs were resuspended in fresh medium (RPMI 1640, 10% FCS) and seeded at 300,000 
cells/well into a 24-well plate followed by incubation with test compounds, efalizumab, efalizumab-
x or controls for 24 h. After one wash with PBS, PBMCs were stained with PE-labelled anti-aLb2 
mAb TS2/4, FITC-labelled anti-CD4 mAb clone A16A1 and APC-labelled anti-CD8 mAb clone 
HIT8a (Biolegend, San Diego, CA) or appropriate isotype controls on ice for 25 min and analyzed 
by flow cytometry. 5,000 events of CD4+ or CD8+ cells were acquired. MFI were calculated using 
the FlowJo software. 
 
For imaging αLβ2 localization, treated cells were washed with cold PBS and fixed at rt for 15 min 
with paraformaldehyde 4% in PBS. Cells were washed, blocked with PBS/2.5% BSA and incubated 
at rt for 15 min. Then the cells were incubated on ice for 30 min with PE-labelled mAb TS2/4 for 
αLβ2 staining, Alexa Fluor® 488-labelled anti-CD107a mAb clone H4A3 (Biolegend, San Diego, 
CA) for lysosomal staining and DAPI (Gibco Life Technologies, Paisley, UK) for nuclear staining. 
After one washing step with PBS, cells were imaged using the ImageStream X Mark II Imaging 
flow cytometer (Merck Millipore Schaffhausen, CH). The number of αLβ2 clusters (granular 
stainings) was quantified using the software ImageJ (NIH, Bethesda, MD). A threshold range of 
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130 - 1,000 mean intensity was applied to all images. Clusters were defined by pixel area size (4 - 
16) plus shape (circularity 0.4 - 1) and were counted as single events. 
 
2.11. Assessment of intracellular ZAP70 phosphorylation or general tyrosine phosphorylation 
ZAP70 tyrosine phosphorylation or general tyrosine phosphorylation were determined using 
phospho-flow analysis. Briefly, PBMCs were rested for 2 h in RPMI containing 2% FCS, 1% MEM 
NEAA (resting medium). Rested cells in ice cold resting medium were added to 5 ml FACS tubes 
and incubated with the small molecule aLb2 inhibitors and DMSO for 30 min and with the control 
MnCl2 for 10 min on ice. On the other hand, OKT3 (5 µg/ml), efalizumab (10 µg/ml) and respective 
IgG controls were incubated with the cells for 15 min on ice. After addition of anti-mouse IgG (5 
µg/ml) or anti-human IgG (10 µg/ml) respectively the incubation on ice was continued for another 
15 min. After these incubation steps, all samples were washed once in ice cold resting medium, 
transferred into a water bath at 37 °C and incubated for 1 min to activate TCR or aLb2-dependent 
membrane proximal signalling pathways. Cells were fixed by addition of paraformaldehyde (final 
concentration 2%) for 10 min at rt. Cells were then washed with ice cold resting medium, 
permeabilized by treatment with ice cold 100% methanol, for 10 min. Cells were washed twice with 
excess of ice cold resting medium and stained for 40 min on ice with Alexa Fluor® 488-labelled 
anti-ZAP70 pY292 (clone J34-602; BD, East Rutherford, NJ) or FITC-labelled anti-phospho-Tyr 
clone pY20 and APC-labelled anti-CD2 mAb RPA-2.10 (Biolegend, San Diego, CA). Antibody 
binding was analyzed by flow cytometry as described above. 
 
2.12. Oral application to rats 
In vivo study in rats. The animal experiments were conducted according to the animal 
experimentation guidelines and laws published by the Swiss Federal and Cantonal Authorities. 
The goal of the study was to assess the pharmacokinetic characteristic of the compound in adult 
male rats upon single dose oral administration.  
Adult male Sprague-Dawley rats (6 weeks; 200-250 g) (Janvier labs, France) have been fed by oral 
gavage with the test compound at the dose levels of 30 mg/kg/day. The test compound was 
suspended in a combination of 60% propylene glycol and 40% macrogol 400. The dose was 
projected to provide adequate therapeutic exposure. Serial blood samples have been withdrawn 
from the tail-vein 0 minute (just before dosing), 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 
hours, 24 hours and 40 hours after dosing for PK analyses. Throughout the dosing interval, animals 
had free access to water and food and were monitored for their behaviour and clinical signs. 
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Key pharmacokinetic parameters assessed included the determination of the area under the curve 
from time zero to infinity (AUCinf), the maximum plasma concentration (Cmax), the time to reach 
maximum concentration (tmax) and the compound's elimination half-life (t1/2). The total blood 
sampling did not exceed 20% of the total blood volume. The plasma samples were collected after 
centrifugation and stored at -20 °C until HPLC analysis.  
 
Plasma sample extraction. Plasma samples were thawed at rt and an aliquot of 30 µl plasma was 
spiked with acetonitrile (60 µl), vortexed and incubated for 10 min at 7 °C to precipitate the plasma 
proteins. The samples were centrifuged at 13,500 rpm for 8 min using the centrifuge Eppendorf 
5424 R (Eppendorf, Schönenbuch, CH) and the supernatant was filtered over a syringe filter (PTFE 
0.45 µm, Sigma-Aldrich, St. Louis, MO).  
 
Chromatography conditions. Plasma samples were analyzed on an Agilent/HP 1100 Series HPLC 
System using a Poroshell 120 EC-C18 column (2.7 um, 50 x 4.6 mm), kept at 35 °C. The test 
compound was detected during a gradient elution at a flow rate of 1.5 ml/min  
using mobile phase A (H2O + 0.1 %V H3PO4) and mobile phase B (acetonitrile). Details of the 
gradients are shown below.  
Gradient:  t= 0.0 min 95 % Solvent A   5 % Solvent B 
   t= 5.5 min   5 % Solvent A 95 % Solvent B 
   t= 7.5 min   5 % Solvent A 95 % Solvent B 
   t= 8.0 min 95 % Solvent A   5 % Solvent B 
 
The compound was measured at a wavelength of 210 nm.  
Standard stock solutions were prepared by dissolving the compound in DMSO at a concentration of 
0.5 mg/ml. The stock solution was kept at 4 °C. Working solutions were prepared on the day of 
analysis by dilution of the stock solutions with the mobile phase solution (3 µg/ml to 0.015 µg/ml). 
Plasma samples were spiked with the working solutions to establish a calibration line from 1000 - 5 
ng/ml. 
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3. Results 
 
3.1. Identification of compound 7130393 as a novel aLb2 inhibitor by virtual screening  
 
3.1.1. Optimisation of screening assay 
For the identification of novel aLb2 inhibitors derived from virtual screening, we selected the 
previously published V well adhesion assay technology. Briefly, in the V well adhesion assay, 
fluorescently labelled leukocytes are allowed to adhere to ICAM-1-coated V well 96-well plates. 
Adhesion was induced by the aLb2 activating divalent cation Mn2+. Thereafter, centrifugal force is 
applied to separate adherent cells from non-adherent cells. Non-adherent cells accumulate in the tip 
of the V-shaped wells and are quantified using a fluorometer with a narrow aperture. In absence of 
inhibitors most of the fluorescent cells stick to the wall of the V shaped wells and cannot be 
detected in the tip of the well, whereas in the presence of inhibitors most of the cells accumulate in 
the tip and will be detected (Fig. 2A) (Weitz-Schmidt and Chreng 2012). This assay was optimized 
using Jurkat cells and commercially available recombinant ICAM-1/Fc fusion protein. Fig. 2B 
shows that increasing concentrations of ICAM-1/Fc resulted in decreasing assay signals, as 
expected. 
 
 
Fig. 2A. Schematic principle of the V well adhesion assay. 
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Fig. 2B. Optimisation of the Jurkat cell/ ICAM-1/Fc V well adhesion assay. Anti-human IgG was 
immobilized on V well microtiter plates at 1 µg/ml and ICAM-1/Fc was added at indicated 
concentrations. Fluorescently labelled Jurkat cells at indicated numbers were transferred to the 
wells and adhesion to ICAM-1/Fc was quantified as described under Materials and Methods. The 
best S/N ratio was obtained by using 300 ng/ml ICAM-1/Fc (15 ng/well) combined with 30,000 
cells/well. 
 
 
Furthermore, the combination of 300 ng/ml ICAM-1/Fc and 30,000 cells/well resulted in acceptable 
assay properties. In seven independent experiments analyzed, the coefficient of variation (CV) of 
the assay varied from 5% to 13% for low controls (Jurkat cell binding in presence of ICAM-1/Fc) 
and from 8% to 14% for high controls (Jurkat cell binding in the absence of ICAM-1/Fc). Signal to 
noise ratios > 7 were achieved in the assay (Table 1). Based on these properties the assay conditions 
described above were applied in the search for novel aLb2 inhibitors. 
 
Table 1 
 Jurkat/ICAM-1/Fc V well assay: coefficients of variation (CV) 
Experiment 
 
1 2 3 4 5 6 7 
Low controls (100% binding) 
Mean (n = 3) 2776 4118 5006 2974 2599 3469 4115 
SD 241 223 374 223 335 226 359 
CV% 8.68 5.42 7.47 7.50 12.89 6.51 8.72 
High controls (background binding) 
Mean (n = 3) 16 630 22 510 27 474 17 098 16 237 25 588 18 642 
SD 1928 3256 3145 2661 1343 3143 2597 
CV% 11.59 14.46 11.45 15.56 8.27 12.28 13.93 
Mean fluorescent counts ± SD of low controls (Jurkat cell binding in presence of ICAM-1 Fc) 
and high controls (Jurkat cell binding in absence of ICAM-1 Fc) run in triplicates of seven 
independent experiments are shown. % CV= SD /mean x 100. 
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3.1.2 Screening of compounds  
In total, 60 compounds derived from the virtual screening approach were purchased from different 
suppliers and tested in the V well adhesion assay at 30 µM. This led to the identification of the hit 
compound 7185446, which inhibited Jurkat cell adhesion to ICAM-1/Fc completely at 30 µM (Fig. 
3). The activity of compound 7185446 during initial screening was superior to the previously 
described aLb2 inhibitor simvastatin (Fig. 3) (Weitz-Schmidt, et al. 2004). All other compounds 
tested were inactive at 30 µM. 
 
 
Fig. 3. Identification of aLb2 inhibitor 7185446. Jurkat cell adhesion to ICAM-1/Fc was quantified in the presence of 
simvastatin at 10 µM and 30 µM (control) and CADD derived compounds at 30 µM using the V well technology as 
described under Materials and Methods. Compound 7185446 completely inhibited adhesion to ICAM-1 at 30 µM. 
ICAM-1 (-): Wells without ICAM-1/Fc (no adhesion); anti-ICAM-1: Wells treated with the anti-ICAM-1 mAb (10 
µg/ml) (inhibited adhesion); ICAM-1: Wells with ICAM-1/Fc (100% adhesion); DMSO solvent control 1%. Sim: 
simvastatin; 5811044, 6680851, 6617296, 55798932, 18682955, 82817783, 6908479: compounds selected by CADD. 
 
3.1.2. Chemical structure and physico-chemical properties of screening hit  
The ‘hit’ identified belongs to the chemical class of succinimides (Table 2). The structure of 
7185446 exhibits similarity with the fungicide procymidone (Campos, et al. 2016) and the 
hydantoin class of aLb2 inhibitors (Table 2) (Giblin and Lemieux 2006). 
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Table 2 
Chemical structures of 7185446, procymidone and BIRT-377 
7185446 Procymidone BIRT-377 
   
Succinimide Succinimide Hydantoin 
3-(3,5-dichlorophenyl)-1-methyl-
6,6-diphenyl-3-
azabicyclo[3.1.0]hexane-2,4-
dione 
3-(3,5-dichlorophenyl)-1,5-
dimethyl-3-
azabicyclo[3.1.0]hexane-2,4-dione 
5(R)-(4-Bromobenzyl)-3-(3,5-
dichlorophenyl)-1,5-
dimethylimidazolidine-2,4-dione 
 
A closer inspection of compound 7185446 revealed that it passes almost all criteria of Lipinski’s 
“rule of five” (i.e. cLogP does not exactly meet target value) which predicts oral absorption (Table 
3) and the possibility to be derivatized towards patentable compounds.  
 
Table 3 
 Physico-chemical properties*. 
 7185446 “Rule of five” criteria 
Molecular weight (Da) 422 < 500 
cLogP 5.42 < 5 
Rotatable bonds  3 - 
H donor 0 < 5 
H acceptor  2 <10 
Form White solid powder - 
* data retrieved from the Chembridge database. 
 
3.1.3 Further characterization of 7185446 and preliminary SAR data 
To obtain preliminary SAR data, commercially available close derivatives of compound 7185446 
were purchased (Table 4). When tested under standard conditions in BSA-containing binding 
buffer, compound 7185446 inhibited Jurkat cell binding to ICAM-1/Fc with an IC50 value of 1.865 
± 1.269 µM (Fig. 4). Under the same conditions, the reference aLb2 inhibitors simvastatin (natural 
statin) (Weitz-Schmidt, et al. 2001) was considerably less active than compound 7185446 (Table 4). 
Moreover, compound 7130393, a close derivative of compound 7185446, inhibited aLb2 with an 
IC50 value of 7.9 µM whereas all other close derivatives analyzed were found to be inactive at 10 
µM (Fig. 4, Table 4). This limited structure-activity-relationship (SAR) suggests that the 3,5 
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dichloro residue of compound 7185446 is essential for activity. The 3,5 dichloro residue has also 
been shown to be crucial for a I allosteric aLb2 inhibitors of the hydantoin class (Giblin and 
Lemieux 2006). 
It needs to be noted at this point that both, 7185446 and 7130393, were more active when tested in 
the presence of 1.5% or 10% FCS instead of 1.5% BSA (Table 4). This result provides evidence 
that the compounds are sequestered by BSA (to different extends) decreasing their apparent 
concentration in the assay. 
 
  
Fig. 4. 7185446 and 7130393 inhibit Jurkat cell binding to ICAM-1/Fc in a dose-dependent manner. Binding of Jurkat 
cells to recombinant ICAM-1/ Fc was quantified in the V well adhesion assay in the presence of increasing 
concentrations of 7185446 or 7130393 as described under Materials and Methods. Representative experiments are 
shown. Each point represents the mean value of triplicates ± SD. 
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Table 4 
Compound 7185446 and close derivatives: Structure-activity relationship. 
Compound 
IC50 [µM] 
1.5% 
 BSA 
IC50 [µM] 
1.5% 
 FCS 
IC50 [µM] 
10% 
 FCS 
Compound 
IC50 [µM] 
1.5%  
BSA 
IC50 [µM] 
1.5%  
FCS 
IC50 [µM] 
10% 
 FCS 
7185446 
 
1.865 ± 
1.269 
0.325 
0.244 
0.304 
6908479 
 
> 10   
6369678
 
> 10   
6370020 
 
>10   
6370940 
 
>10   
7037690 
 
>10   
7130393 
 
7. 948  0.835 
7137311 
 
>10   
7145474 
 
>10   
7208094  
 
>10   
Procymidone 
 
 
>10   
Simvastatin  
 
7.726   
Chembridge database ID; IC50 values of independent experiments run in triplicates shown; some compounds 
were tested in presence of FCS or BSA at different concentrations. 
	
3.1.4. Selectivity of compounds 7185446 and 7130393 
To assess the selectivity of 7185446 and 7130393 over other members of the integrin family, the 
effect of the compounds on VLA-4-mediated cell adhesion was assessed. VLA-4 is a non-I domain 
containing integrin which mediates lymphocyte adhesion to its ligand VCAM-1. For this purpose, 
the V well technology described above was adapted to the VLA-4/VCAM-1 integrin/ligand pair by 
measuring Jurkat cell binding to recombinant VCAM-1/Fc immobilized onto V well plates. Jurkat 
cells express both integrins, aLb2 and VLA-4. The assay was validated with the potent VLA-4 
inhibitor RO0505376 which blocked cell adhesion with an IC50 of 9.5 nM (Fig. 5B). In contrast, 
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7185446 and 7130393 were inactive in the VLA-4 adhesion assay at 30 µM demonstrating high 
selectivity of the compounds for aLb2 over the integrin VLA-4 (Fig. 5A). 
 
A) 
 
B) 
 
 
Fig. 5. 7185446 and 7130393 did not affect VLA-4-mediated adhesion. (A) The adhesion of fluorescently labelled 
Jurkat cells to recombinant VCAM-1/Fc immobilized onto V well plates was quantified in presence of solvent control, 
the VLA-4 inhibitor RO0505376 at 3 µM and the aLb2 inhibitors 7185446 and 7130393 at 30 µM. The assay was 
performed as described under Material and Methods. Each bar represents the mean value ± SD of triplicates. VCAM-1 
(-): Wells without immobilized VCAM-1; VCAM-1: VCAM-1/Fc coated well containing 1% DMSO (solvent 
control); (B) IC50 determination of VLA-4 inhibitor RO0505376. 
 
3.1.5. Reversible inhibition of the aLb2/ICAM-1 interaction by 7185446 
To assess whether 7185446 is a reversible or irreversible inhibitor of the aLb2/ICAM-1 interaction, 
Jurkat cells were treated with compound or solvent (DMSO), washed and then assayed for ICAM-1 
binding in the V well adhesion assay. As shown in Fig. 6, binding was restored after washing. This 
demonstrates that 7185446 is a reversible inhibitor of aLb2-mediated adhesion.  
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Fig. 6. 7185446 is a reversible inhibitor of the Jurkat/ICAM-1 interaction. Fluorescently labelled Jurkat 
cells were simultaneously activated with Mn2+ and treated with the aLb2 inhibitors 7185446 at 10 µM or 
solvent (DMSO 0.1%) for 30 min. After treatment one group was immediately tested for binding to 
ICAM-1/Fc immobilized onto V well plates in presence of the compounds or DMSO whereas the “wash” 
group were rinsed three times with binding buffer and then tested for adhesion as described under 
Materials and Methods. Data shown are the mean values of triplicates ± SD. ICAM-1 (-): Control wells 
without ICAM-1/Fc. 
 
3.1.6. Effect of 7185446 on cell viability 
The effect of 7185446 on cell viability was assessed using the ToxiLight™ Bioassay Kit and the 
CellTiter-Glo® Luminescent Cell Viability Assay. Jurkat cells were incubated for 24 h with the 
compound at 0.1 µM, 1 µM and 10 µM. 7185446 did not induce toxicity and did not impair cell 
viability up to 10 µM (Fig. 7A and B). In the same experiments cyclosporine A at 10 µM 
significantly induced toxicity by 2.3 fold compared to solvent control (DMSO 0.1%) (Fig. 7A) and 
reduced cell viability by 78.7% at 10 µM after 24 h of exposure (Fig. 7B). Triton X and amiodarone 
were used as positive controls for cytotoxicity. 
 
A) 
 
B) 
 
Fig. 7. Cytotoxicity was evaluated by measuring the release of adenylate kinase (A), and the intracellular content of 
ATP (B) in Jurkat after 24 h of incubation. In both assays, 7185446 is not cytotoxic at 0.1, 1 and 10 µM. DMSO 0.1% 
solvent control; Triton X 0.5%; amiodarone 50 µM; CsA: cyclosporine A 0.1, 1, 10 µM. Each bar represents the mean 
value ± SD of triplicates. 
 
3.1.7. Compound 7185446 belongs to the class of α I allosteric inhibitors 
7185446 was identified by ligand-based similarity searching from known αL I allosteric aLb2 
modulators (Giblin and Lemieux 2006). αL I allosteric inhibitors are known to impair the reactivity 
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of the anti-aLb2 mAb R7.1 (Weitz-Schmidt, et al. 2004) but not the reactivity of the anti-aLb2 
mAb TS2/4 (Weitz-Schmidt, et al. 2011).  
mAb R7.1 recognizes a combinational epitope that requires both the aL I and the b propeller 
domain on the aL chain for full reactivity (Weitz-Schmidt, et al. 2011).  
Therefore, we investigated the effect of 7185446 on R7.1 and TS2/4 binding to aLb2. 7185446 
reduced the reactivity of mAb R7.1 in a concentration-dependent manner whereas the binding of the 
mAb TS2/4 was not affected by the compound (Fig. 8A and B). This result further substantiates that 
7185446 belongs to the class of αL I allosteric modulators which are known to stabilize integrins in 
their inactive state.  
 
A)                                 R7.1 
 
B)                              TS2/4 
 
Fig. 8. Inhibition of mAb R7.1 binding to Jurkat cell aLb2 by 7185446. (A) Jurkat cells were incubated with FITC-
labelled mAb R7.1 in the presence of DMSO (1%) or increasing concentrations of 7185446. The experiment was 
performed in the presence of Mn2+ and Mg2+. Bound antibody was quantified by flow cytometry. Yellow line: isotype 
control; orange line: 7185446 10 µM, red line: 7185446 3 µM; violet line: 7185446 1 µM; green line: 7185446 0.3 µM; 
black line: DMSO 1%. 
(B) Jurkat cells were incubated with PE-labelled mAb TS/4 in the presence of 1% DMSO or 30 µM 7185446. The 
experiment was performed in assay buffer containing Mn2+ and Mg2+. Bound antibody was quantified by flow 
cytometry. A representative experiment out of two independent experiments is shown. Black line: isotype control; blue 
line: DMSO 1%; red line: 7185446 30 µM. 
 
In conclusion, the first hit which emerged from the CADD approach fulfilled the criteria of 
inhibition of aLb2-dependent adhesion, lack of cytotoxicity, allosteric mode of action, molecular 
weight < 500 Da, and drugability. This prompted us to initiate a chemistry program with the goal to 
improve the activity and the physicochemical properties of the hit compound 7185446. 
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Sample Name Count Geometric Mean : FL1-H Mean : FL1-H Median : FL1-H
Jurkat IsoFITC.001 30000 3.40 4.24 3.31 
Jurkat R7.1 AP59 10uM.010 30000 5.34 5.90 5.51 
Jurkat R7.1 AP59 3uM.009 30000 6.14 6.84 6.39 
Jurkat R7.1 AP59 1uM.008 30000 8.82 9.70 9.22 
Jurkat R7.1 AP59 0.7uM.007 30000 10.7 11.7 11.1 
Jurkat R7.1 AP59 0.3uM.006 30000 16.5 18.7 17.4 
Jurkat R7.1.002 30000 26.7 31.9 30.0 
10 0 10 1 10 2 10 3 10 4
TS2/4:PE
0
200
400
600
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un
t
Sample Name Subset Name Geometric Mean : FL2-H Median : FL2-H Mean : FL2-H
jurkat iso PE.002 Ungated 3.80 3.42 7.37 
jurkat TS2_4.004 Ungated 183 212 239 
jurkat TS2_4 AP59 30uM.006 Ungated 166 195 217 
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3.1.8. Hit optimisation and SAR  
 
Compound 7185446 was modified based on the preliminary SAR data described in section 3.1.3. 
and CADD feedback. The chemical derivatisation program was conducted in order to optimize 
activity and physicochemical properties of the hit compounds while maintaining a molecular weight 
of ~ 500 Da. The synthesis of the derivatives is depicted in Fig. 9. 
 
 
 
Fig. 9. Synthesis of aLb2 antagonists 7a-y. Reagents and conditions: a) acetic acid, reflux, 5 h, 1a: 66%, 1b: 67%; b) 
for 4a- 4d: 4-toluenesulfonohydrazide, MeOH, rt; for 4e- 4h: hydrazine, EtOH, reflux; c) for 5a- 5d: 15% NaOH, 
toluene; for compounds 5e – 5h: MnO2, CH2Cl2, 30 min. rt; d) 4-acetamidobenzenesulfonylazide, DBU, MeCN, rt; e) 
toluene, 80 °C; If R2 ≠ R3, a mixture of two diastereomers was obtained. The diastereoisomers were separated by 
chromatography. If R2 is phenyl or a substituted aromatic ring, the H-NMR signals for the H2 and the H6-proton of the 
dichloroaniline group, are shifted from 7.5 ppm (2a or 2b) to 6.2 – 6.5 ppm. Compounds 7h – 7y are racemates. 
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Starting from the hit compound 7q (=7185446) the influence of the substituents R1, R2 and R3 on 
the activity was tested (Table 5). The influence of the methyl function (R1) at the succinimide ring 
revealed the following: if one proton at the succinimide ring is replaced by a methyl function, the 
activity is enhanced (i.e. 8-fold in case of compound 7t (R1 = CH3, IC50 [µM] = 0.016) and 7g (R1 = 
H, IC50 [µM] = 0.132)) (Table 5). The SAR analysis for substituent R2 revealed that there is a need 
for aryls in the endo position at the three membered ring. This is reflected by the observation that 
the activity of the compounds 7a, 7c, 7h, 7k, 7m or 7o is in the range of 0.147 to 3.3 µM whereas 
the respective diastereomers 7b, 7d, 7i, 7l, 7n and 7p where R2 is H, are inactive (Table 5). It needs 
to be noted that the endo configuration is consistent with a chemical shift of the dichloroaniline 
protons H2 and H6 from 7.5 ppm to 6.2 - 6.5 ppm. Next, we investigated the impact of the 
substituent R3 at the three membered ring on the activity of the compounds. Compounds with R3 = 
H, aryl, CO2Et or morpholine amide were measured. Table 5 and 6 show that no definite trends for 
R3 = H, ester or amide were detected. However, it can be clearly observed, that if R3 is an aryl 
substituent, the activity is improved (Table 5). 
Further, according to the cLogP values the chemical derivatization program resulted in less 
lipophilic compounds as compared to the hit compound 7q. cLogP values were reduced from 5.42 
(hit compound 7q) to 2.83 (compound 7x) by introducing solubilizing groups such as carboxyethyl 
(compound 7v), nitrile (compound 7r) or morpholine amide (compound 7x) (Table 5).  
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Table 5 
Chemical structure, MW, cLogP and biological activity of novel aLb2 inhibitors  
Code MW (Da) cLogP R1 R2 R3 IC50 [µM] 
7a 332.18 3.67 H C6H5 H 2.753, 1.587 
7b 332.18 3.67 H H C6H5 > 10 
7c 411.08 4.42 H p-C6H4Br H 3.326 
7d 411.08 4.42 H H p-C6H4Br > 10 
7e 408.28 5.19 H C6H5 C6H5 9.119 ± 3.722 (n=3) 
7f 516.28 5.87 H p-C6H4CN p-C6H4OCF3 0.963 
7g 516.28 5.87 H p-C6H4OCF3 p-C6H4CN 0.132 
7h 346.21 3.96 CH3 C6H5 H 1.544 ± 0.646 (n=3) 
7i 346.21 3.96 CH3 H C6H5 > 10 
7k 425.10 4.69 CH3 p-C6H4Br H 0.472 ± 0.180 (n=5) 
7l 425.10 4.69 CH3 H p-C6H4Br > 10 
7m 430.21 5.08 CH3 p-C6H4OCF3 H 0.495 ± 0.213 (n=3) 
7n 430.21 5.08 CH3 H p-C6H4OCF3 > 10 
7o 371.22 3.77 CH3 p-C6H4CN H 0.471 ± 0.407 (n=3) 
7p 371.22 3.77 CH3 H p-C6H4CN > 10 
7q 422.30 5.42 CH3 C6H5 C6H5 1.865 ± 1.269 (n=21) 
7r 472.33 4.88 CH3 p-C6H4CN p-C6H4CN 0.045 ± 0.014 (n=3) 
7s 590.30 7.33 CH3 p-C6H4OCF3 p-C6H4OCF3 0.101 
7t 531.31 6.10 CH3 p-C6H4OCF3 p-C6H4CN 0.016 ± 0.012 (n=10) 
7u 531.31 6.10 CH3 p-C6H4CN p-C6H4OCF3 0.595, 0.530 
7v 497.17 4.72 CH3 p-C6H4Br CO2Et 0.375 ± 0.204 (n=3) 
7w 538.22 3.80 CH3 p-C6H4Br 
 
3.496 
7x 484.33 2.83 CH3 p-C6H4CN 
 
0.636 
7y 543.32 4.08 CH3 p-C6H4OCF3 
 
0.480 
The activity of the compounds was determined in the aLb2-dependent V well adhesion assay. IC50 values 
± SD of > 3 independent experiments run in triplicates or IC50 values of a single experiment run in 
triplicates are shown. cLogP values were calculated using the online tool ALOGPS 
(http://www.vcclab.org/lab/alogps/). 
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Table 6 
Influence of the substituent R3 on the activity. 
 
 
H 
 
CO2Et  
 
p-C6H4CN 
 
p-C6H4OCF3 
p-C6H4Br 0.472 0.375 3.496 - 0.076* 
p-C6H4CN 0.471 - 0.636 0.045 0.562 
p-C6H4OCF3 0.495 - 0.480 0.016 0.101 
R1 = CH3; IC50 [µM]; *IC50 value derived from the diastereomer mixture. 
 
The racemate of the hit compound 7q and the most active compound 7t were separated by 
chromatography on a chiral column. We found that enantiomer I was 2 or 100 times more active 
than enantiomer II, respectively (Table 7). Moreover, enantiomer I of compound 7t was > 300 fold 
more potent than enantiomer I of compound 7q (Table 7). 
 
Table 7 
From hit compound 7q (=7185446) to lead compound 7t 
 
 
7q 7t 
IC50 [µM]: 1.865 ± 1.269 (racemate) IC50 [µM]: 0.016 ± 0.013 (racemate) 
(= compound 7185446) (=Compound 1) 
IC50 [µM]: 1.544 ± 0.646 (n=3) (enantiomer I) IC50 [µM]: 0.005, 0.004 (enantiomer I) 
IC50 [µM]: 3.690, 5.360 (enantiomer II) IC50 [µM]: 0.573 (enantiomer II) 
 
Several derivatives shown in Table 4 represent promising novel aLb2 inhibitors. Below the 
properties of compound 7t, also termed “Compound 1”, are described in more detail. The activity, 
selectivity, cytotoxicity and first PK data of this compound are presented. Moreover, studies are 
described which address potential unwanted agonist-like downstream effects of Compound 1 such 
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as induction of activation epitopes, unwanted outside-in signalling, cytokine release or aLb2 
internalization.  
 
3.2. aLb2 inhibitor Compound 1 
 
3.2.1. Characterization of aLb2 inhibitor Compound 1  
Compound 1 blocked aLb2 mediated Jurkat cell adhesion to immobilized ICAM-1 with an IC50 of 
0.016 ± 0.012 µM (Table 8).  
In the selectivity Jurkat/VCAM-1 adhesion assay Compound 1 did not impair the adhesion 
indicating selectivity for aLb2 over VLA-4 (Table 8). 
Moreover, profiling in a mouse specific aLb2 adhesion assay revealed that the α I allosteric 
inhibitor Compound 1 exhibited ~ 40 fold greater potency towards inhibition of human versus 
murine aLb2 (Table 8). Such limited cross-species reactivity have been also observed for LFA878, 
another α I allosteric aLb2 inhibitors (Mancuso, et al.2016). 
Compound 1 was not cytotoxic to Jurkat cells or the liver cell line HepG2 after 24 h of incubation 
as determined by the release of the enzyme AK from damaged cells (Table 8). Moreover, 
Compound 1 did not induce apoptosis and/or necrosis in Jurkat cells after 24 h of exposure, in 
contrast to the control compounds staurosporine and amiodarone (Table 8) (Felser, et al. 2013). 
 
Table 8 
Activity profile of aLb2 Compound 1. 
Assay 
Compound 1 
IC50 [µM] 
Activity (aLb2) 
Jurkat/ICAM-1  
0.016 ± 0.012  
Selectivity (VLA-4) 
Jurkat/VCAM-1 
> 10 
Cross-reactivity (mouse aLb2) 
OT-1/mICAM  
0.629 ± 0.100 
Cytotoxicity (AK release) 
Jurkat cells > 10 
Cytotoxicity (AK release) 
HepG2 cells 
> 10 
Cytotoxicity (Annexin V / PI) 
Jurkat 
> 10 
(n=3) 
Data were generated as described under Material and 
Methods. Mean values ± SD of ≥ 3 independent 
experiments run in triplicates or single values run in 
triplicates are shown. 
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3.2.2. Quantification of mAb R7.1 to aLb2 in whole blood of different species 
Next, we were interested to determine the binding of Compound 1 to aLb2 in the presence of all 
blood components. For this investigation, we utilized a recently validated whole blood technology 
which determines mAb R7.1 mAb to aLb2 (Welzenbach, et al. 2015). We applied this technology 
not only to human but also to whole blood of rabbits. We found that Compound 1 reduced the 
binding of mAb R7.1 to aLb2 in a concentration-dependent manner on lymphocytes, monocytes 
and granulocytes. Compound 1 showed potent activity with IC50s in the range of low micromolar 
(Table 9). Surprisingly, first data indicate that Compound 1 was more active in blood samples from 
rabbit than from human (Table 9). These findings together suggest that Compound 1 efficiently 
binds to aLb2 in the presence of all blood components. Further, they show that Compound 1 fully 
cross-reacts with rabbit aLb2. Compound 1 shares this property with other a I allosteric inhibitors 
(Weitz-Schmidt, et al. 2004). 
The effect of Compound 1 on the binding of mAb R7.1 in whole blood from mice and pigs could 
not be assessed because R7.1 did not cross-react with mouse aLb2 (shown previously) or with pig 
aLb2 (shown here for the first time), respectively.  
 
Table 9 
Binding of mAb R7.1 in whole blood from different species. 
 
 
 
 
 
 
 
 
IC50 ± SD of three independent experiment (Homo sapiens, Hs) 
or single IC50 determination (Oryctolagus cuniculus, Oc) are 
shown. Sus scrofa (Ss), Mus musculus (Mm). 
 
3.2.3. Compound 1: impact on aLb2 conformations 
The allosteric mode of action of Compound 1 was confirmed by quantifying the binding of the anti-
aLb2 mAb R7.1 to Jurkat cells. Under resting conditions, Compound 1 and simvastatin (the statin 
was included in the experiment as a positive control) induced R7.1 epitope loss on the a chain as 
expected for a I allosteric inhibitors (Fig. 10A). The IC50 value measured for Compound 1 in the 
R7.1 epitope loss assay was IC50 2 ± 2 nM (Fig. 10B), and thus in the range of the IC50 determined 
in the aLb2 V well adhesion assay (Table 8). 
The conformational state of aLb2 upon Compound 1 binding was further studied using two other 
well-characterized, conformation-sensitive mAbs mapping to distinct sites of aLb2. MEM148 
recognizes an epitope on the hybrid domain of the b2 chain that becomes exposed when the integrin 
 Allosteric mode of action - REMA IC50 [μM] 
 Hs Oc Ss Mm 
Lymphocytes 0.247 ± 0.141 - - - 
Monocytes 0.158 ± 0.069 0.049 - - 
Granulocytes 0.247 ± 0.141 0.055 - - 
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adopts an extended, active conformation (Tang, et al. 2005). The epitope of the second mAb m24 is 
uncovered when the b2 I-like domain is activated, i.e. mAb m24 epitope exposure is characteristic 
for the activated conformation of this domain (Chen, et al. 2010a). We found that both epitopes 
were not induced in presence of Compound 1 (Fig. 10C and E) demonstrating that Compound 1 
does not mediate aLb2 extension and b2-I-like domain activation, in contrast to what has been 
observed for a/b I allosteric aLb2 inhibitors (Mancuso, et al. 2016) (Shimaoka, et al. 2003) 
Interestingly, under Mn2+ activating conditions (Mn2+ is known to increase integrin affinity by 
replacing Ca2+ at the ADMIDAS site of the b2 I-like domain (Chen, et al. 2010b)), a differential 
effect of Compound 1 on MEM148 and m24 epitope exposure was noted. Compound 1 suppressed 
Mn2+-induced MEM148 epitope expression (Fig. 10D) but allowed Mn2+-mediated mAb 24 epitope 
exposure (Fig. 10F). This finding indicates that the a I allosteric inhibitor Compound 1 stabilizes 
the bent conformation of aLb2 not only under resting but also under activating conditions 
(Shimaoka, et al. 2003) (Sen, et al. 2013b). However, the result also shows that Compound 1 allows 
Mn2+-induced b2 I-like domain activation (as monitored by m24 epitope expression) in the absence 
of extension (Fig. 10F). Remarkably, a similar ‘cocked’ conformation with b2 I-like domain 
activation, despite the presence of a bent conformation has been also noted in a crystal structure of 
the closely related integrin aX/b2 (Sen, et al. 2013a). Moreover, the aLb2 conformational states 
observed in this study for Compound 1 resembles those observed upon binding of the a I allosteric 
αLβ2 inhibitor LFA878 (statin derivative) (Mancuso, et al. 2016), indicating that the distinct 
conformations observed in this study are characteristic for the a I allosteric mode of action. 
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A) R7.1 
 
B) R7.1 
 
C) MEM148 
 
D) MEM148 
 
E) m24 
 
 
F) m24 
 
Fig. 10. Effect of Compound 1 on the conformational status of aLb2 under resting and Mn2+ activating 
conditions. (A) Cells were exposed to DMSO (0.1%), Simvastatin (100 µM) and Compound 1 (10 µM), 
for 40 min. At 40 min the binding of mAb R7.1 (reports a I allosteric inhibitor binding to aL/b2) was 
quantified by flow cytometry. Each bar represents the mean value ± SD of triplicates. (B) R7.1 epitope 
loss was quantified by flow cytometry in the presence of indicated concentrations of Compound 1. Each 
point represents the mean value ± SD of three independent experiments. 
(C) The binding of mAb MEM148 (reports aL/b2 extension) or (E) mAb m24 (reports b2 I-like domain 
activation) was quantified by flow cytometry. Each bar represents the mean values ± SD of ≥ three 
independent experiments. (D) Jurkat cells were exposed to Compound 1 in the presence of Mn2+ and 
control in the presence and absence of Mn2+ for 24 h at above indicated concentrations. The binding of 
mAb MEM148 and (F) mAb m24 was determined by flow cytometry. Each bar represents the mean value 
± SD of four independent experiments (D) or of triplicates (F). 
Fold change to control was calculated as the ratio of the geometric MFI (gMFI) value of the test sample 
and gMFI value of the respective control. The ratio of controls was set to 1. Statistical significance was 
determined using one-way analysis (ANOVA) (*** p < 0.001 and **** p < 0.0001 vs DMSO control; # p 
< 0.05 vs second comparison). 
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3.2.4. Compound 1 does not induce protein tyrosine phosphorylation 
After proving that Compound 1 does not induce aLb2 activation epitopes, we investigated the 
effect of the compound on aLb2 mediated outside-in signalling. We reasoned that the lack of 
agonistic effects such as activation epitope induction will also translate into an absence of 
(unwanted) outside-in signalling. 
In order to prove this hypothesis, we assessed zeta-chain-associated protein kinase of 70 kDa 
(ZAP70) tyrosine phosphorylation in PBMCs treated with Compound 1. ZAP70 is an established 
early mediator of aLb2 outside-in signalling and constitutively associated with aLb2 (Evans, et al. 
2011). PBMCs were used for this study instead of Jurkat cells to avoid the limitations inherent to T-
leukemic cells lines when studying signalling events. We found that Compound 1 did not trigger 
detectable ZAP70 Y292 phosphorylation in CD2+ T cells, in contrast to the integrin activating 
cation Mn2+ or cross-linked anti-CD3 mAb OKT3 (OKT3-x) (Fig. 11A). mAb OKT3 binds to CD3 
of the TCR/CD3 complex and is used to induce signalling pathway normally triggered upon binding 
of the natural ligand peptide antigen-major histocompatibility complex (pMHC) to the TCR 
(Houtman, et al. 2005). These signalling pathways lead to phosphorylation of various proteins on 
tyrosine residues including ZAP70 (Houtman, et al. 2005). Moreover, in agreement with the above 
data, Compound 1 did not lead to detectable general protein tyrosine phosphorylation in CD2+ T 
cells, in contrast to Mn2+ and OKT3-x (Fig. 11B, Table 10). 
Taken together, under experimental conditions tested, Compound 1 did not induce aLb2 mediated 
outside-in signalling as assessed via protein tyrosine phosphorylation.  
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A)               Phospho ZAP70 (pY292) 
 
B)                                Phospho-Tyr 
 
Fig. 11. Effect of Compound 1 on the phosphorylation state of ZAP70 or protein tyrosine phosphorylation in general. 
PBMCs were treated with Compound 1 (10 µM), controls DMSO (0.1%), MnCl2 (2mM)/DMSO (0.1%) (Mn2+ 
activates aL/b2) or cross-linked anti-CD3 mAb OKT3 (OKT3-x; 5 µg/ml) (activates the TCR signalling pathway) 
were pre-incubated on ice and then activated for 1 min at 37 °C. The binding of (A) anti-ZAP70 pY292 (J34-602) 
mAb and (B) anti-pTyr (PY20) mAb was quantified in CD2+ lymphocytes by flow cytometry. Each bar represents the 
mean value ± SD of three independent experiments (different donors, single determinations each). Statistical 
significance was determined using one-way analysis (ANOVA) (**** p < 0.0001 vs DMSO). 
 
3.2.5. Cytokine release 
Subjects treated with the anti-aLb2 mAb efalizumab showed an increase of IL-6 plasma level by 
90-fold after two hours of administration (Prater, et al. 2014). This increase was still detectable after 
two days. This prompted us to assess whether a small molecule aLb2 inhibitor, such as Compound 
1 could also induce unwanted cytokine release. THP-1 cells were treated with Compound 1, 
efalizumab or respective controls for 24 h. PMA/Ionomycin and LPS were used as positive control 
stimuli (Jones, et al. 2003). After 24 hours of incubation Compound 1 did not induce IL-6 release in 
THP-1 (Fig. 12, Table 10). In contrast, there was a clear trend towards IL-6 induction in presence of 
efalizumab alone and cross-linked, confirming the observation made in patients treated with 
efalizumab. 
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Fig. 12. Compound 1 did not induce IL-6 release. THP-1 cells were untreated or were treated with Compound 1, (10 
µM) and the control DMSO (0.1%), efalizumab (10 µg/ml) or efalizumab-x (10 µg/ml) and the respective controls IgG 
(10 µg/ml) and IgG-x (10 µg/ml). PMA (10 ng/ml), Ionomycin (Iono) (1 µM) and LPS (1 µg/ml) served as assay 
controls. Mean values ± SD of nine independent experiments are shown. 
 
3.2.6. Compound 1 does not affect aLb2 expression 
Previous data show that aLb2 engagement by efalizumab induces a rapid downmodulation of aLb2 
in psoriasis patients by more than 70% in T cells (Vugmeyster, et al. 2004) (Mortensen, et al. 2005) 
(Guttman-Yassky, et al. 2008). Thus, we investigated the effect of Compound 1 on aLb2 surface 
expression using resting PBMCs. The cells were treated for 24 h with inhibitors and aLb2 
expression was determined on CD4+ and CD8+ T cells. In agreement with previous observations in 
psoriasis patients, efalizumab led to a downmodulation of aLb2 in CD4+ and CD8+ T cells which 
became more evident when the antibody was cross-linked (Fig. 13A and B). In contrast, even high 
concentrations of Compound 1 (> 500 x IC50 value) did not significantly affect aLb2 surface 
expression (Table 10). 
Moreover, consistent with previously published data (Coffey, et al. 2004) cross-linked efalizumab 
induced aLb2 clustering, internalization and co-localisation within the lysosomal compartment 
(Fig. 13 C, F and G). In contrast, aLb2 cell surface expression and lysosomal localization in 
presence of Compound 1 was indistinguishable from the respective solvent control (Fig. 13C, D and 
E). Taken together these data point towards fundamental differences between Compound 1 and 
efalizumab regarding the effect on aLb2 internalization, and lysosomal degradation. 
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D) DMSO 
 
E) Compound 1 
 
F) IgG-x 
 
G) Efalizumab-x 
 
Fig. 13. Effect of Compound 1 and efalizumab on the localisation of aLb2. PBMCs were treated with Compound 1 (10 
µM), efalizumab (10 µg/ml) or efalizumab-x (10 µg/ml) and the respective controls DMSO (0.1%), IgG (10 µg/ml) and 
IgG-x (10 µg/ml) for 24 h. After 24 h aLb2 surface expression on (A) CD4+ and (B) CD8+ T cells was determined by 
the binding of fluorescently labelled mAb TS2/4 using flow cytometry. Each bar represents the mean value ± SD of 
three independent experiments. Statistical significance was determined using one-way analysis (ANOVA) (* p < 0.05, 
** p < 0.01, *** p < 0.001 and **** p < 0.0001 vs respective controls). (C) aLb2 clusters (granular stainings) were 
quantified in inhibitor-treated PBMCs by flow-based imaging and image analysis. Clusters were defined by pixel area 
size (4-16) plus shape (circularity 0.4-1) and were counted as single events. Each bar represents the mean value ± SEM 
of 1,000 images analyzed. A representative experiment out of two independent experiments is shown. (D) Localisation 
of aLb2 in presence of DMSO, (E) Compound 1, (F) IgG-x or (G) efalizumab-x was visualized using flow-based 
imaging. aLb2 was labelled with mAb TS2/4-PE (red), lysosomes with anti-LAMP-1 mAb H4A3-FITC (green) and the 
A) CD4+ 
 
 B) CD8+ 
 
C) PBMCs 
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nucleus with DAPI (blue). Co-location of aLb2 and LAMP-1 staining is indicated in yellow. Individual cells are 
displayed by multispectral imaging of brightfield (BF). Representative images are shown. 
 
In conclusion, Compound 1 is a potent a I allosteric aL/β2 inhibitor which apparently lacks 
unwanted agonist-like effects observed with other aL/β2 pharmacologies. The profile of Compound 
1 is summarized in Table 10. 
 
Table 10 
Overview of in vitro effect profiles of Compound 1. 
aLb2 inhibitor Compound 1 
Mode of action α I allosteric 
Selectivity of mode of action  aLb2 
Inhibition of aLb2 adhesion  + 
Induction of aLb2 activation epitopes  - 
ZAP70 phosphorylation - 
Tyrosine phosphorylation - 
aLb2 internalization - 
Cytokines release induction - 
+: effect, -: no effect 
 
3.2.7. Oral application study  
On the basis of its exceptional in vitro profile, Compound 1 was evaluated in vivo. Adult male 
Sprague-Dawley rats were fed by oral gavage with the test compound at the dose levels of 30 
mg/kg/day. A summary of the PK parameters obtained following po dose of Compound 1 to rats is 
shown in Table11. The plot of the mean Compound 1 plasma concentrations over time is shown in 
Fig. 14. 
 
In summary, this initial single oral dose PK study in rats showed that Compound 1 at a dose level of 
30 mg/kg was orally available, achieving exposure levels well in excess of the expected human 
effective dose (estimated based on human IC50 in vitro). The high volume of distribution suggested 
an at least 2-compartimental distribution. Drug clearance was close to hepatic drug flow. HPLC 
analyses of the PK samples identified a single peak without major peaks indicative of major 
metabolites. Treatment was well-tolerated without gross abnormalities in animal behaviour. 
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Fig. 14. Pharmacokinetic profiles after a single oral 
(po) dose of Compound 1. Each point represents the 
mean Compound 1 plasma concentrations of three 
different animals ± SD. 
Table 11 
Pharmacokinetic parameters for Compound 1. 
Species Rat 
Cmpd Compound 1 
Route PO 
Dose 30 mg/kg 
Rsq 1 
t1/2 58 h 
tmax 4 h 
Cmax 138 ng/ml 
Cmax/D 4.61 (ng/ml)(mg/kg) 
AUCINF 3930 h*ng/ml 
AUCINF/D 131 (h*ng/ml)(mg/kg) 
VzF 639 L/kg 
CLF 7.64 L/h/kg 
 
 
4. Discussion 
Computer aided drug design (CADD) is an important tool in drug discovery and development that 
can reduce time and expense requested for the development of new drugs.  
In the current study, we conducted a virtual screening approach to identify a novel class of small 
molecule aLb2 inhibitors of an a I allosteric mode of action, taking advantage of the published 
structural information for this leukocyte integrin. The a I allosteric mode of action was pursued 
because it promises to introduce strict aLb2 target selectivity and to avoid paradoxical agonism, i.e. 
to potentially resolve unwanted phenomena alternative aLb2 targeting modes of action were found 
to be associated with.  
 
The hit molecule identified by virtual screening exhibited micromolar activity, displayed selectivity 
over the integrin VLA-4, exhibited reversible binding and was free from cytotoxicity in the assays 
applied. The subsequent derivatisation program had three major objectives: (1) to improve the 
activity and (2) to enhance the hydrophilicity of the chemical scaffold while (3) maintaining a low 
molecular weight in the order of 500 Da. Several compounds fulfilling these objectives were 
synthesized. The most active compound identified so far (enantiomer of Compound 1) exhibits an 
IC50 value in the single-digit nanomolar range in a cell-based adhesion assay, representing one of 
the most active aLb2 inhibitors described to date. Importantly, first data indicate that Compound 1 
is able to efficiently bind to aLb2 in the whole blood compartment, supporting the expectation of 
biologic effect in a clinically relevant compartment. Further, the compound was shown to be orally 
available. When delivered to rats at 30 mg/kg it resulted in plasma levels over the human IC50 value 
0 6 12 18 24 30 36 42 48
1
10
100
1000
time (h)
C
om
po
un
d 
1 
ng
/m
l
Paper 1 
 63 
(in vitro data) for up to 24 h. This property favourably differentiates Compound 1 from some other 
a I allosteric inhibitors and a/b I allosteric inhibitors which exhibit poor oral bioavailability 
(Zhong, et al. 2012). 
 
However, we also noted limited cross-species reactivity when we profiled our compounds in the 
mouse specific αLβ2-dependent OT-1 adhesion assay. This limited cross-species reactivity has been 
also observed with other a I allosteric inhibitors and may be explained by the difference in the 
amino acids sequence of the I domain (Mancuso, et al. 2016). This limited cross-species reactivity 
needs to be taken into account when selecting experimental animal diseases for assessing potential 
therapeutic effects of the compounds. 
  
In line with our previous study (Mancuso, et al. 2016) we could also demonstrate that the novel 
class of a I allosteric inhibitors described here does not exhibit unwanted agonist-like effects 
typically observed for aLb2 targeting antibodies or a/b I allosteric αLβ2 inhibitors. Our study 
further underlines that a I allosteric aLb2 inhibitors can be favourably differentiated from these 
inhibitor classes in terms of their downstream effects. 
 
Taken together these results show that we discovered a new class of aLb2 inhibitors with an 
encouraging in vitro profile and with promising properties to be investigated in vivo towards 
potential drug candidate selection and further development. 
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2. Discussion 
 
“A drug is a substance which, if injected into a rabbit, produces a paper.” 
Otto Loewi 
3 Jun 1873 - 25 Dec 1961 
German-American physician, physiologist and pharmacologist 
 
2.1. Back to the future 
Crude extracts from wild plants, herbs, roots, vines and fungi constituted the first medicines that 
were used mainly for the relief of pain and suffering, to heal wounds, and to treat maladies. The 
first “painkiller” used was the juice obtained from the opium poppy plant (Papaver somniferum) 
and it can be dated to the ∼3,000 BC (Jones 2011). 
For the first synthetic drug, we need to wait until the 1832 when chloral hydrate was discovered by 
Justus von Liebig. Its sedative properties were first published in 1869; it is still available today in 
some countries (Liebig 1831) (Liebig 1832). 
In ancient times, drug discovery was mainly based on the accumulation of experience from 
generation to generation, the Ebers Papyrus can be considered the first written record of medical 
therapeutics. It is a 20 meters long papyrus of 110 pages dating to ∼1500 BC. It was purchased at 
Luxor in 1872 by the German egyptologist and novelist Georg Ebers and it was named after him.  
In the Ebers Papyrus it is possible to find the description of hundreds of treatments for the diseases 
inflicting ancient Egyptians. These treatments were prepared by mixing together herbs, leaves, 
minerals, and animal excreta (Jones 2011). 
The early history of drug discovery is therefore all about natural products and herbal remedies, the 
use of which dates back thousands of years. The driving force in their discovery was mainly 
serendipity. 
Nowadays there is a shift from serendipity to rationality in drug discovery that is more and more 
based on the knowledge of the biological system and on the development of modern chemistry. This 
allowed the discovery of highly specific and selective new drugs (Chen and Du 2007). 
 
2.2. Drug discovery 
In pharmacology, biotechnology and medicine, drug discovery is the process of identification, 
creation, or design of a compound or a complex that could become a therapeutic (Wyatt, et al. 
2011). 
This process requires a big investment in time and money, a single new drug can cost up to 1 billion 
euros and take 10-14 years to develop and there is no guarantee about the end result (Chen and Du 
2007). 
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A drug target is a broad term which can be applied to a range of biological entities which may 
include for example proteins, genes and RNA and the specific binding site for a drug through which 
the drug exerts its action (Overington, et al. 2006). 
A good target needs to be druggable. Druggability defines a biological target that is known to or is 
predicted to bind with high affinity to a drug, be it a small molecule or larger biologicals. Further, 
upon binding, the drug must elicit via the target a therapeutic benefit to the patient, this effect may 
be measured both in vitro and in vivo. A good target needs to be efficacious, safe and meet clinical 
and commercial needs (Hughes, et al. 2011). 
 
2.3. Target identification 
 
Our drug target is the integrin αLβ2. This integrin is expressed on the cell surface of leukocytes and 
it mediates the adhesion of leukocytes to each other and to other cells, thereby regulating leukocyte 
trafficking, T cell costimulation and immunological synapse (IS) formation (Hogg, et al. 2011). 
αLβ2 is also centrally involved in immune-mediated diseases of high medical need, including 
chronic plaque psoriasis, multiple sclerosis, rheumatoid arthritis, small vessel vasculitis, dry eye 
disease and transplantation indications, among other diseases (Zecchinon, et al. 2006). In several of 
these diseases, αLβ2 has been validated by biologic therapies as a target of high therapeutic 
potential (Nicolls and Gill 2006). 
 
2.4. Target validation 
 
Target validation is defined as a pharmacologic, physiologic and pathologic process that evaluates a 
biomolecule during the development of pharmaceuticals for therapeutic application. 
This process can be performed at the molecular, cellular, or whole animal level (Chen and Du 
2007). 
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This validation could be for instance chemical/biological or genetic. In the chemical/biological 
validation the use of drugs or proteins provides evidence that the inhibition of a target results in 
inhibition of its activity.  
In the genetic validation, using knockdown methodologies it is possible to suppress the target (i.e. 
gene knockout) with a dominant-negative approach (Wyatt, et al. 2011). 
In case of αLβ2, mAbs validated the integrin as a promising therapeutic target. The anti-αLβ2 mAb 
efalizumab was efficacious in patients with psoriasis. Moreover, preclinically anti-αLβ2 mAbs were 
efficacious in transplant and autoimmune disease models (Nicolls and Gill 2006). 
Another validation of αLβ2 comes from subjects affected by leukocyte adhesion deficiency (LAD). 
Mutations in β2 chain can lead to LAD. LAD-I has been identified in patients having a deficiency 
in β2 (CD18) integrins. LAD-I is characterized by recurring bacterial and fungal infections, 
impaired wound healing and severe gingivitis, patients also exhibit impaired leukocyte adhesion, 
and reduced trafficking to inflammatory sites (Becker and Lowe 1999) (Hogg and Bates 2000). 
LAD provides a genetic validation of our target. 
 
2.5. Assay development 
 
Once a target has been identified and validated the following step is the development of screening 
assays that allows the identification of hits.  
Cell-based assays are usually used to target classes such as membrane receptors, nuclear receptors 
and ion channels. These assays provide a functional read-out as consequence of the activity of the 
compound (Michelini, et al. 2010). 
The primary cell-based in vitro screening assay optimised to identify novel αLβ2 inhibitors was the 
V well assay.  
Compared with standard adhesion assays, the V well adhesion assay avoids washing steps and 
involves precisely controlled centrifugal forces to separate adherent from non-adherent cells. In this 
way the variations are reduced, the assay is more reliable and reproducible. This method has been 
validated with different classes of adhesion molecule families (selectins and integrins) and is 
adaptable to several other adhesive interactions. The time necessary to perform the assay is also 
reduced compared with standard adhesion assay and it can be readily utilized for high throughput 
applications. Moreover, it may be applied to diagnose disease associated with cell adhesion defects 
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such as LAD (Weitz-Schmidt and Chreng 2012). Potential hits active in the V well adhesion assay, 
able to inhibit the interaction between αLβ2 and ICAM-1, were then planned to be screened in 
another assay to identify their inhibition mode. The in vitro assay used to determine the allosteric 
mode of action of the compounds was the reporter epitope assay. For the measurement of α I 
allosteric inhibitor binding to αLβ2, the anti-αL chain mAb R7.1 was selected. mAb R7.1 binds to a 
region involving the C-terminal linker of the αLβ2 I domain located on the αL chain and the β 
propeller located on the β2 chain of αLβ2 (Weitz-Schmidt, et al. 2011). All α I allosteric inhibitors 
(of diverse chemical scaffolds) investigated to date with this antibody consistently induced R7.1 
epitope loss (Welzenbach, et al. 2002) (Shimaoka, et al. 2003) (Weitz-Schmidt, et al. 2004). The 
sensitivity of the R7.1 epitope to α I allosteric inhibition can be considered to be established for the 
entire class of inhibitors. 
Furthermore, we developed a whole blood assay that allows the correlation of compound/αLβ2 
interactions with therapeutically relevant, downstream biological effects. 
This methodology based on flow cytometry technology allow to simultaneously assess and 
correlate, at the single-cell level, inhibitor-specific αLβ2 conformational change, αLβ2 expression 
and T cell activation in human whole blood (Welzenbach, et al. 2015). 
 
2.6. Hit identification 
 
Computer aided drug design (CADD) offers valuable tools for the in silico identification of 
compounds, minimizing the risk of later rejection and saving time, money and resources. 
“Fail fast, fail early”, this is the new philosophy beyond the systems which could immediately 
reports and indicate a possible failure (Katsila, et al. 2016), and it was the driving force since the 
beginning of the project. 
In this project, CADD has been used to identify novel allosteric inhibitors that modulate αLβ2 
function via binding to the I allosteric site.  
The availability of crystal structure information and different chemical lead compounds facilitates 
computer-assisted drug design. The CADD approach pursued addressed the task of finding novel 
hits and leads from two conceptually complementary angles: (1) ligand-based and (2) structure-
based similarity. A collection of several million commercially available compounds with drug-like 
properties has been compiled. These virtual screens yielded in ranked lists of compounds tested in 
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vitro in the adhesion assay. The first hit emerged from the V well adhesion assay approach fulfilled 
the selected criteria: inhibition of αLβ2-dependent adhesion with an IC50 in the low mM range, lack 
of in vitro cytotoxicity, allosteric mode of action, molecular weight < 500 Da, selectivity over the 
integrin VLA-4, druggability and patentability. 
Moreover, our first hit bound the target in a reversible manner, this kind of compounds are favoured 
because their effects can be more easily ‘washed-out’ following drug withdrawal, an important 
consideration for a drug supposed to be used in patients (Hughes, et al. 2011). 
 
2.7. Hit to lead 
 
The output of the hit identification in a drug discovery process should be usually a molecule, 
typically with potency in the range of 0.100 to 5 mM against the drug target. Our first hit, in line 
with this statement, shows an IC50 of ~ 1.9 mM in inhibiting the adhesion of Jurkat cells to 
immobilized ICAM-1. Next step in the project was a chemistry programme to improve the potency 
of the hit (Hughes, et al. 2011). 
We proceeded with intensive SAR investigations around the core compound structure (Hughes, et 
al. 2011), also paying attention to the physicochemical properties. Solubility and permeability 
assessments are crucial for a compound to be a drug, to access to the circulation if injected or to be 
adsorbed in the digestive system (Hogg and Bates 2000). 
 
2.8. Lead optimization 
 
Lead optimization is a stage of the drug discovery process in which the chemical structures of 
compounds or biologics are modified to improve target specificity and selectivity, 
pharmacodynamic and pharmacokinetic, and toxicological properties to produce a preclinical drug 
candidate. 
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Our lead, Compound 1, blocked αLβ2 mediated Jurkat cell adhesion to immobilized ICAM-1 with 
an IC50 of 16 nM.  
In the selectivity Jurkat/VCAM-1 adhesion assay, Compound 1 did not impair the adhesion, 
indicating selectivity for αLβ2 over VLA-4. Moreover, profiling Compound 1 activity in a mouse 
specific αLβ2 adhesion assay, our lead compound exhibited greater potency toward inhibition of 
human versus murine αLβ2, (IC50: 630 nM). Such limited cross-species reactivity can be explained 
by the fact that the identity between the amino acid sequence of the human I domain and the murine 
I domain is 74.7%.  
Concerning the toxicological properties, Compound 1 did not induce in vitro cytotoxicity in the 
human lymphoblastoid cell line Jurkat and in the human liver cell line HepG2 and apoptosis and/or 
necrosis in Jurkat cells. Compound 1 also showed in vitro stability in human and rat plasma. 
To differentiate our lead compound from other existing αLβ2 pharmacologies, we compared 
Compound 1 to the α I allosteric inhibitors LFA878, the α/β I allosteric inhibitor XVA143 and the 
monoclonal antibody anti-αLβ2 efalizumab. These are different inhibitor classes with different 
mode of actions. Although these inhibitors have in common that they potently block αLβ2 function 
in vitro, they exert differential effects on the conformation of αLβ2, its expression, on ZAP70 
protein levels and the internalization of engaged TCR/CD3 complex. 
Compound 1, in contrast to XVA143, did not induce activation epitopes in the β2 chain of αLβ2, a 
striking feature of the α/β I allosteric αLβ2 inhibitor class characteristic for the extended, 
intermediate affinity form of αLβ2. This induced extended, intermediate affinity form is associated 
with a phenomenon called ‘rolling adhesion’. 
Furthermore, Compound 1, in contrast to anti-αLβ2 mAb, did not induce the unscheduled 
internalization of surface αLβ2 and its subsequent lysosomal translocation in leukocytes. This effect 
is not unique to the anti-αLβ2 mAb efalizumab. It has also been noted in other anti-αLβ2 mAb 
antibodies that bind close to or within the ligand binding site of αLβ2. 
Moreover, we found that efalizumab affected the downmodulation of engaged TCR/CD3. While the 
TCR was normally internalized, the downregulation of CD3 was markedly reduced in presence of 
efalizumab. A similar dissection of TCR/CD3 complex expression has been observed in psoriasis 
patients treated with efalizumab (Vugmeyster, et al. 2004) (Guttman-Yassky, et al. 2008). 
Our research into the mechanism of this phenomenon revealed that efalizumab-induced 
internalization of αLβ2 was associated with reduced ZAP70 levels. As ZAP70 is constitutively 
bound to αLβ2 (Evans, et al. 2011), these reduced ZAP70 levels may be explained by enhanced 
concomitant transport of ZAP70 and αLβ2 to the lysosome and potential degradation. 
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Moreover, it is tempting to speculate that αLβ2 internalization leading to reduced ZAP70 levels and 
disturbed expression of engaged TCR/CD3 may contribute to or may even constitute the basis of 
the unique state of T cell hyporesponsiveness observed in efalizumab treated patients (Guttman-
Yassky, et al. 2008) (Koszik, et al. 2010) (Kuschei, et al. 2011). 
In contrast to efalizumab and α/β I allosteric inhibitors, α I allosteric αLβ2 inhibitors did neither 
internalize αLβ2 nor reduce ZAP70 protein levels and, as a consequence, allowed for the 
simultaneous internalization of engaged TCR/CD3. 
In the light of these favourable results, Compound 1 was assessed for oral bioavailability in vivo in 
rats where it showed to be absorbed and detectable in plasma. 
It is possible to further optimize compound characteristics by knowing how fast a drug is 
metabolized and cleared from the body, the fraction of the drug administered that enters systemic 
circulation upon dosing, the volume of plasma the dose dissolved in, and the estimate of the dose 
required in humans using animal models (Hughes, et al. 2011). 
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3. Outlook 
 
The next major step in our project will be to assess the efficacy of the selected lead compounds in 
an animal disease model (Whiteside and Kennedy 2010). Animal disease models are designed to 
simulate some pathological conditions of the human. Animal models are essential for translation of 
drug findings from bench to bedside (Denayer, et al. 2014).  
The presence of lymphocytes strongly expressing αLβ2 adjacent to the ICAM-1 expressing cells 
suggests that the interaction of ICAM-1 with αLβ2 is important in the development of ocular 
inflammation in uveitis in humans (Uchio, et al. 1994). mAbs directed against αLβ2 or ICAM-1 can 
be used to protect against experimental uveitis (Uchio, et al. 1994). For those reasons, animal 
models of autoimmune uveitis can be suitable for POC.  
To date no animal model can reproduce the full complexity of the human disease, it is necessary to 
develop and use a variety of models to represent the different aspects and diverse clinical/ 
immunological manifestations of uveitis. Experimental autoimmune uveitis (EAU) is induced by 
immunization of animals with the retinal antigens known to elicit responses in lymphocytes isolated 
from patients with uveitis (Caspi 2010). 
There are mouse models of experimental autoimmune uveitis well characterized and validated. 
These models already helped in elucidating the genetic influences, dissecting the basic mechanisms 
of pathogenesis and testing novel immunotherapeutic paradigms (Caspi, et al. 2008). 
Rabbit models of experimental uveitis are promising to test the efficacy of compounds that target 
the α I domain because of the high homology score between human αLβ2 and rabbit αLβ2. 
 
The dissection of the different mechanisms of αLβ2 inhibition by their downstream effect profiles, 
as established by this study, the proof of concept in animal models will be of high relevance for 
future therapeutic translation of these modes of action.  
In this context, it is intriguing to note that our αLβ2 inhibitory mechanism of action, which is 
devoid of unwanted downstream effects, remains the only mechanism of action not advanced to 
clinical proof-of-concept, to date. 
Not suspected initially, the heavy reliance of preclinical research on murine disease models of 
autoimmunity may have contributed to this lag in translation. While α I allosteric inhibition have 
been shown to be highly effective in certain murine experimental disease models (Zhong, et al. 
2012) (Wan, et al. 2003) (Suchard, et al. 2010), mice (for their limited cross-species reactivity) may 
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not be the best suited species to explore the full therapeutic potential. A second reason for the 
limited progress made with α I allosteric inhibitors in the past, compared to the other 
pharmacological mechanisms assessed in this study, may be their strict selectivity for αLβ2, by 
itself. The α I allosteric mechanism of action is neither expected to affect β2 integrins other than 
αLβ2, in contrast to what has been observed with α/β I allosteric inhibitors (Shimaoka, et al. 2003) 
(Welzenbach, et al. 2002), nor to affect the expression of other major immune receptors as observed 
with the antibody approach (Vugmeyster, et al. 2004) (Guttman-Yassky, et al. 2008). Indeed, a 
strictly αLβ2 selective pharmacology may not be best-suited to support conventional therapeutic 
concepts of suppressive immune modulation. Innovative therapeutic concepts, educated and guided 
by the exceptionally well-characterized biologic functions of αLβ2, may be required to realize the 
therapeutic potential of an exclusively αLβ2 selective pharmacology, eventually. 
 
 “The whole is more than the sum of its parts” 
Aristotle 
384–322 BC 
Greek philosopher and scientist 
 
 
Drug discovery is a multidisciplinary process where different fields of knowledge come across, and 
where people with different background need to work together aiming for a common result. 
The success of a project, the medical and scientific advances, are often built on the back of a 
synergic work. 
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